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Though widely believed to exist, few convincing examples of genetic interactions 
have been detected through statistical approaches in genome-wide association studies.  
The first piece of work in this thesis attempts to determine if there is evidence for the 
existence of such interactions within genes identified through protein-protein 
interactions.  A software package is developed and applied to data from a recent 
publically available genetic study.  No evidence was found for an enrichment of such 
interactions in the available data. 
The second study applies three current methods for interaction detection to a real data 
set with compelling evidence of an interaction.  Sparse Partitioning, SNPHarvester 
and Random Jungle were selected, with the later two being followed by the 
HyperLasso as a post-processing step. Only one method, SNPHarvester, was able to 
detect the interaction. 
The third study outlines a local pilot project in renal transplant dysfunction.  Genetic 
variants from donors and recipients are examined using survival analysis. Interactions 
between the two genomes are tested for an effect on the survival time of the kidney.  
Secondary renal phenotypes of acute rejection and progression to end-stage renal 
failure are also considered.  There were no strongly significant associations 
discovered in this data. 
The final study is a multi-centre renal transplant study analysing over 2000 donor 
recipient pairs throughout the UK and Ireland.  Although much larger than the pilot, 
this study also failed to detect any associations with graft survival time or the 
secondary phenotypes.  SNPHarvester was applied to the data and there are some 
indications of potential interactions, but replication is essential before the results can 
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be trusted.  An outline of an extension to SNPHarvester to better handle survival data 
is presented. 
 
Results from all of these studies were largely negative. Detecting interactions in 
genome-wide data remains a difficult task.  Narrowing the search space by filtering 
may be a better approach than attempting a genome-wide search, though 
SNPHarvester has proven to be useful and is a good choice if a true genome-wide 
search is required.  
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In recent years the field of genetics has benefitted from significant advances in 
technology.  Measuring a person's genetic makeup is becoming increasingly faster 
and cheaper, however an understanding of how this variability affects us and makes 
us who we are is more difficult to achieve.  Many hundreds of thousands, or even 
millions, of pieces of genetic information can be available for every individual.  
Making sense of the vast amount of genetic information is a daunting task.  
Additional non-genetic measurements and an ever-increasing number of possible 
outcomes complicate the picture further.  Simple statistical approaches have met with 
some success but a deeper understanding of the complex genetics behind many 
human traits may be possible with further methodological development.  This is 
particularly true in the field of renal transplantation where, as I will explain later, the 
success of the transplant can be viewed as a complex trait with important 
implications for the health of the recipient. 
1.1 Human Genetics 
The human genome contains the genetic material that, combined with the 
environment in which we develop and live, determines our physical characteristics.  
Either directly or in combination with environmental factors, it determines our sex, 
eye colour, hair colour, height and many other physical characteristics, as well as our 
predisposition to certain medical conditions and diseases.  The way in which our 
genome is read and interpreted, and its instructions carried out, is summed up 
concisely in what is called the central dogma of molecular genetics. 
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1.1.1 Proteins and the Central Dogma of Molecular Biology 
Proteins are essential to life.  They make up about 45% of the mass of a human, and 
are present in skin, hair, muscles, and just about any structure within the human 
body.  Proteins act as enzymes, are involved in communications between cells ('cell 
signalling'), and act as antibodies, a critical part of the immune system that keeps us 
healthy.  In fact, most basic cellular processes could not occur without proteins.  
Some proteins come from the food we eat, but many are produced by the body.  
In 1958 Francis Crick first stated the 'Central Dogma' of genetics: 
This states that once ‘information’ has passed into protein it cannot get out again. In 
more detail, the transfer of information from nucleic acid to nucleic acid, or from 
nucleic acid to protein may be possible, but transfer from protein to protein, or from 
protein to nucleic acid is impossible. Information means here the precise 
determination of sequence, either of bases in the nucleic acid or of amino acid 
residues in the protein.   
(Crick, 1958) 
Crick restated this in Nature in 1970: 
The central dogma of molecular biology deals with the detailed residue-by-residue 
transfer of sequential information. It states that such information cannot be 
transferred back from protein to either protein or nucleic acid. 
(Crick, 1970) 
It is often put somewhat more simply: 
"DNA makes RNA makes protein." 
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To understand the central dogma, it is important to understand proteins, DNA, RNA, 
and why they are important. 
A protein is formed from a linear chain of amino acids which then folds into a final 
three-dimensional shape.  There are 12 amino acids synthesized by the human body, 
and these are joined up in various sequences to form different proteins.  The 
sequence of amino acids dictates which protein is produced following processes 
called transcription and translation.  
1.1.2 Genes, transcription and translation 
All humans (and most living organisms) carry their genetic makeup in a molecule 
called deoxyribonucleic acid (DNA).  DNA exists in long strands in the nucleus of 
almost every cell in the body.  A single strand of DNA is a polymer; this means it is 
a molecule that is formed by many similar molecular units bonded together linearly.  
The smaller molecular units, or monomers, are called nucleotides.  There are four 
nucleotides that make up DNA; cytosine, guanine, adenine and thymine.  A unit of 
three nucleotides bonded together in sequence is called a codon.  Most codons 
encode a specific amino acid, or indicate the beginning or end of the coding 
sequence of a gene (start/stop codons).  A gene is considered to be a basic unit of 
heredity of an individual, and each one contains the sequence of bases that dictate the 
amino acid sequence that makes up a single protein.  
Molecules of ribonucleic acid (RNA) are formed in the nucleus of a cell during a 
process called transcription.  RNA molecules share many of the properties of DNA.  
A strand of RNA is also a sequence of nucleotides bonded together in a chain. In 
RNA, however, the nucleotide thymine is not present; instead it is replaced by uracil.  
Another difference is that DNA is double-stranded - two strands align together and 
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the bases bond together in a specific manner to form the double-helix ladder-like 
structure of a DNA molecule.  Between the two strands, cytosine will bond only with 
guanine and adenine only with thymine.  Because of this the two strands are 
'compliments' of each other, and the sequence of one strand is predicted entirely by 
the other strand.  During transcription an enzyme called RNA polymerase separates 
the two strands, reads the sequence on one strand, and creates a complimentary 
strand of RNA from this template.  The sequence of bases on the RNA molecule is 
completely complementary to the sequence on the DNA molecule except that where 
a thymine is expected, it is replaced with a uracil on the RNA strand.   
After a strand of RNA is produced, sections of it are removed ('spliced') in a process 
called post-translational modification.  Non-coding sequences can exist between 
genes but also inside them, and the non-coding sequence must be spliced out of the 
RNA so that only the correct amino acids are include in the protein.  A region of 
protein-encoding sequence within a gene is called an exon; a non-coding region 
within a gene is called an intron. 
Translation is the process by which a cell produces a protein using RNA.  The RNA, 
after the non-coded regions have been spliced out, acts as a template for the amino 
acid sequence.  A cellular complex called the ribosome reads the template and 
attaches amino acids in the correct sequence, indicated by the codons, to form the 
protein. 
1.1.3 Chromosomes and the Size of the Human Genome 
Each haploid set of chromosomes in a human contains 3 billion bases, for a total 
diploid set of 6 billion bases. There are approximately 23 000 protein-encoding 
genes, and only about 1.5% of the human genome is actually protein-coding 
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sequence.  The exact function of the rest of the DNA is not known exactly, but some 
regions play a role in regulating how much protein is produced.  Genes are not 
always being transcribed and translated; a gene whose protein product is currently 
being produced is said to be 'expressing'.  Regulatory regions can control the 
expression levels of a gene. 
DNA is folded and wrapped around structural proteins called histones to form a very 
dense structure called a chromosome.  Chromosomes are located in the nucleus of a 
cell.  The normal human genome is made up of 2 copies of each of 23 chromosomes.  
One pair of chromosomes determines the sex of the individual; females have two 
copies of the X chromosome, while males have one X and one Y chromosome.  The 
other 22 pairs of chromosomes are referred to as 'autosomal' chromosomes.  Each 
parent of an individual donates a single chromosome towards each of the 23 pairs, 
hence 50% of the genetic material is inherited from the mother and 50% from the 
father. 
1.1.4 Recombination and Linkage Disequilibrium 
A chromosome inherited from a parent is created from a combination of their two 
chromosomes.  The genetic material of the two chromosomes is combined in a 
process called recombination.  On average, each of a parent's chromosomes 
contributes 50% of their genetic material to the chromosome inherited by the 
offspring.  The points at which chromosomes cross over and recombine are not 
random; some places are for more likely to have a crossover event than others, 
leading to areas called recombination hotspots.  Between these hotspots, chunks of 
DNA are likely to be inherited together, leading to highly correlated sequences in 
these regions.  Correlation between polymorphisms due to physical proximity on a 
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chromosome is called linkage disequilibrium (LD).  Between any two loci on the 
same chromosome this can be measured by calculating the square of the correlation 
coefficient that would be obtained by coding alleles as 0 or 1 and observing their co-
occurrence.  This measure is referred to as r2, and requires that the sequence of 
variants on each of an individual's chromosomes is known.  Assigning variants to 
each chromosome can be done in a process called phasing.  R2 is often more 
conveniently estimated without resorting to phasing by coding each locus as carrying 
0,1 or 2 copies of an allele and observing the within-individual co-occurrence of 
these values.  An r2 of 1 indicates perfect correlation between two loci, and the allele 
at one locus can always be perfectly predicted by the allele at another.  An r2 of 0 
indicates a completely random relationship between the two loci.  This local LD is 
crucial to the success of genome-wide association studies, as it allows a single 
variant on a GWAS panel to represent or 'tag' a large number of common variants 
around it. 
1.2 History of genetic association studies 
1.2.1 Discovering molecular markers 
A molecular marker for a genetic study is a fragment of DNA that is measurable, 
identifiable, and varies between individuals.  These markers can be as small as single 
nucleotide or involve longer lengths of DNA sequence.  The marker itself may not 
directly influence a trait or diseases, but will 'tag' regions of the genome that differ 
between individuals.  The underlying assumption is that people with the same 
genetic markers will have inherited the same DNA sequence near that marker, 
including variants that are not directly measured.   
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Early genetic studies used markers called restriction fragment length polymorphisms 
(RFLPs) in tests of associations. DNA is cleaved at specific locations called 
restriction sites.  Variability in the length of the resulting DNA fragments, as 
measured by techniques such as the Southern blot, indicate heritable changes in the 
DNA sequence between restriction sites. These can result from several types of 
genetic variation such as insertions or deletions of DNA, variable number tandem 
repeats (VNTRs), translocations, or changes in the sequence of the restriction site 
itself.  These polymorphisms can be used in genetic analyses to identify regions of 
the genome associated with traits or diseases.  RFLP analysis is useful but the 
process is slow and labour-intensive. 
 
The discovery of polymerase chain reaction (PCR) methods to amplify DNA 
simplified the discovery of molecular markers. Oligonucleotides called primers are 
designed to match sequences flanking the region of DNA to be amplified.  The DNA 
sequence between these sites is replicated in a series of heating and cooling cycles. 
Replication is exponential since the newly-generated DNA is amplified along with 
the original DNA in subsequent cycles.  The PCR products can then be run through a 
gel which separates fragments of different lengths. In genetic studies PCR was 
commonly used to identify microsatellites, which are short sequences (2-6 base 
pairs) of nucleotides that repeat.  The number of repeats and the length of the 
microsatellites vary between individuals, making them useful markers.  
 
In 1977 Fred Sanger developed a method now referred to as Sanger sequencing.  
"Sequencing" refers to techniques which determine the exact sequence of nucleotides 
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in a strand of DNA.  In Sanger's method, single-stranded DNA is replicated in vitro 
in four separate tubes, each one containing all 4 nucleotides plus small amounts of 
one of four "ddNTP" molecules.  ddNTPs are the same as nucleotides but they 
prevent the bonding of further nucleotides and terminate the DNA strand. Thus, all 
strands in the "G" tube are known to terminate with guanine. However the strands 
will be different lengths, because the ddNTP will be incorporated randomly at any 
position where guanine can bond.  The products from all four tubes are then run side-
by-side on a gel which separates the DNA strands by length. The order of the strands 
by fragment lengths indicates the position in the sequence, and the nucleotide at that 
position is determined by the tube in which the fragment was produced.  The 
development of Sanger sequencing was a large step forward in the field of genomics, 
though it has now been largely replaced by the introduction of high-throughput 
parallel sequencing methods such as Solexa sequencing and 454 pyrosequencing. 
However it is still considered to be a 'gold standard' method, and it is still used to 
verify the results of other techniques and for small sequencing projects.  
 
1.2.2 Mapping the genome 
 
The development of Sanger sequencing made it possible to consider reading the 
DNA sequence of large regions of the genome.  Beginning in 1990, the Human 
Genome Project aimed to read not just selected regions, but the entire DNA sequence 
of a human genome. The first draft of the human genome appeared 10 years later 
(Lander et al, 2001), and the final draft was published three years later. Further 
reference genomes have been sequenced and published since, notably through the 
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HapMap project (International HapMap Consortium, 2003) and the 1000 Genomes 
project (1000 Genomes Project Consortium, 2010). Projects such as these have 
enabled the creation of a 'reference genome' using samples from multiple individuals. 
The reference genome identifies nucleotides present at every locus, including 
information on allele probabilities at polymorphic sites across different ethnic 
groups.  Data from all of these studies is freely available to researchers for use in 
their own genetic studies. 
Information gathered from projects such as the Human Genome Project and the 
HapMap project made it possible to identify much of the variation across the human 
genome.  This information allows researchers to design techniques to measure 
genetic variation down to the level of the single SNP, and to investigate how this 
variation is associated with human traits and diseases.  
1.2.3 Family studies 
Genetic studies based around families and patterns of inheritance have been used to 
investigate diseases that are common within families. Given a family pedigree, 
genetic marker information and disease information, the aim is to try to identify 
markers which cosegregate with the diseases phenotype and might therefore identify 
a region containing a causal genetic defect.  A family-based linkage analysis may use 
a parametric model specifying the mode of inheritance, or a non-parametric model 
which assumes no inheritance model. A popular tool is the transmission 
disequilibrium test (TDT) (Spielman 1993). Heterozygote parents should pass on 
either allele to their offspring with equal probability.  The TDT tests whether 
affected offspring carry certain alleles more frequently than would be expected given 
that they have heterozygote parents.  The presence of alleles at high frequency in 
affected offspring could indicate that a causal variant near the tested allele is 
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inherited in affected individuals.  Spielman et al applied this test to families with 
Type 1 Diabetes, classifying individuals into 3 allele groups based on an RFLP near 
the insulin gene. They discovered that one allele group was much more frequently 
inherited than the other two combined (p=0.004), giving evidence for linkage in this 
region.  The TDT test is still useful today as it avoids problems which can occur in 
population studies, such as population structure.  It is also used to identify regions for 
fine-mapping or sequencing to identify causal variants. 
 
1.2.4 Candidate gene studies 
Before it was possible to affordably and efficiently measure genetic variation across 
the genome, researchers often focused their investigations on a particular gene or set 
of 'candidate' genes they believed to be involved with a disease.  Studies were then 
designed using this candidate gene list along with available information on SNPs in 
or near these genes.  Individuals both with (cases) and without (controls) the disease 
were tested for polymorphisms at these SNPs. Allele frequencies in cases and 
controls were compared and tested, assuming that a large difference could indicate a 
SNP that was near a causal variant and therefore inherited with it.  An advantage of a 
candidate gene study is that it is targeted at a small number of SNPs, and therefore 
fewer tests are carried out than in other approaches.  This reduces the probability of 
false positive results due to chance. 
This approach depends heavily on investigators' ability to predict which genes are 
associated with disease and may lead to missing associations that weren't predicted.  
Candidate gene studies have therefore not always successful at finding SNP-diseases 
associations in the absence of strong prior evidence for a particular gene or locus.  
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However if this evidence is available, this approach is still useful for fine-mapping 
loci identified by other means.  
1.3 Genome-wide Association Studies 
1.3.1 Genotypes and Phenotypes 
A popular design for genetic studies is the genome-wide association study, or 
GWAS.  Typically, genetic material is collected from the blood or saliva of study 
participants and 'genotyped' using a commercially prepared chip.  Genotyping 
involves reading single bases of an individual's DNA sequence at many points 
throughout the genome.  A base position in the genome where individuals vary is 
called a single-nucleotide polymorphism, or a SNP.  The SNPs that are read by 
genotyping chips are generally picked to be on the chip because they are known to 
vary between individuals. Reading information at a locus where all individuals 
always carry the same base does not provide us with any information about 
differences between people.  SNPs are also selected to try to capture as much 
common variation in the genome as possible.  There are many SNPs which are not 
genotyped, but they may be 'tagged' by other SNPs in the region in high linkage 
disequilibrium; that is, with high r2 values. A great deal of effort has gone into 
reading the sequence of many individuals to create a set of reference genomes for 
people of different ancestry (International HapMap Consortium, 2003, 1000 
Genomes Project Consortium, 2010a). It has been shown that this genetic variability 
can help to explain why people display different physical characteristics, or 
phenotypes (Wellcome Trust Case Control Consortium, 2007).  Phenotypes observed 
in individuals can be checked for association with genetic variability.  This is the 
premise behind the genome-wide association study.   
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After a sample has been placed on a genotyping chip and processed, the data that is 
produced for analysis is a sequence of letters which represents an individual's alleles 
carried at many hundreds of thousands, or even millions of SNPs.  The SNPs on a 
typical genotyping chip are usually bi-allelic; that is, there are only two alleles 
present at that locus in the population.  Each individual at each locus caries two 
alleles; one from each chromosome.  A person can carry two copies of one allele, 
two copies of the other allele, or one copy of each allele.  A person carrying two 
copies of the same allele is a homozygote, while someone carrying one copy of each 
is a heterozygote.  The alleles are often referred to by their relative frequency in the 
population; the allele at greater than 50% frequency is the major allele, while the 
other is the minor allele. 
 
1.3.2 Quality Control 
Genotyping is not a perfect science, and care must be taken in considering which 
SNPs to analyse.  Poor genotyping and heterogeneous sampling can lead to many 
false association signals.  There are many simple checks that can be carried out to 
ensure that the SNPs and samples that are analysed are of high quality (Weale, 2010, 
Anderson et al., 2010). 
1.3.2.1 Sample Quality Control 
Sample quality control aims to remove samples which were poorly genotyped, 
identify samples which may have been misidentified, identify ethnic outliers and 
identify samples from related individuals.  Several summary statistics can be useful 
in finding such samples. 
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1.3.2.1.1 Sample missingness 
Large amounts of missing data in a sample indicate a poorly genotyped sample.  
These samples are generally removed, as bias can be introduced if DNA quality 
varies with phenotype.  This type of non-random missingness can lead to differential 
allele frequencies between cases and controls which may be interpreted as 
association signals. 
1.3.2.1.2 Gender checks 
Gender checks are a useful check of sample labelling.  If the gender of individuals is 
available from the sample information, this can be compared to the genetically-
determined gender.  Large numbers of mismatches could indicate either incorrect 
sample labelling or an incorrect step in the data management process, and further 
investigation is required to ensure that the sample information and genotypes are 
correctly matched.  Less prevalent mismatches could indicate problems within 
subsets of samples, for example mislabelling if samples from one centre.  Gender 
checks can also be used to filter out rare instances of medical conditions such as 
Klinefelter's syndrome (XXY syndrome), in which a male carries an extra copy of 
the X chromosome.  These samples with indeterminate gender are usually excluded. 
Gender checks are usually performed by calculating proportions of heterozygosity 
for SNPs on the X-chromosome.  Females with two copies of the X-chromosome 
will have SNP genotypes in Hardy-Weinberg equilibrium (HWE).  A locus which is 
in HWE is showing the expected amount of heterozygosity given the allele 
frequencies for these SNPs and assuming random mating with respect to these loci.  
Males should have no heterozygosity on the X-chromosome as they carry only one 
copy; they should be hemizygotes (carriers of a single allele) for these SNPs.  These 
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hemizygotes are typically coded as homozygotes in GWAS data sets and so will 
appear to be extremely divergent from HWE. 
1.3.2.1.3 Relatedness and duplication 
Duplicated and related samples will be more similar genetically to each other than 
would be expected in unrelated samples.  This similarity could lead to differences in 
allele frequencies that could be confounded with phenotypes, leading to false 
association signals.   Relatedness between individuals from the same population can 
be determined by working out the expected allele sharing between individuals given 
the allele frequencies of a SNP in the population.  Averaging this value across all 
SNPs for a pair of individuals gives their 'identity by state' (IBS) value.  IBS values 
can be converted to 'identity by descent' (IBD) values, which are estimates of the 
proportion of alleles they share due to recent common ancestors (Purcell et al., 
2007).  These pairwise IBD estimates will cluster around certain values for well-
defined close relatives.  Duplicates and monozygotic twins will have IBD of 1, while 
1st-degree relatives (parent-child, full siblings) will have IBD of around 0.5.  
Second-degree relatives such as grandparent/grandchild, half-siblings, aunt/niece 
will have an IBD of about 0.25.  Third-degree relatives such as cousins have an IBD 
of about 0.125.  In a GWAS it is generally advisable to remove one of any pair with 
IBD somewhere between second and third degree relatives, and perhaps even lower 
if the resolving power to distinguish these cases from the general sample distribution 
of IBD is available.  Generally the sample with the greater amount of missingness is 
removed.  The remaining samples will then have a reasonable amount of allele-
sharing as expected amongst unrelated individuals within the population being 
studied. 
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1.3.2.1.4 Ethnicity outliers 
Alleles occur at different frequencies in different populations. Phenotypes can also 
be associated with different populations; for example cardiovascular disease has a 
prevalence of 15% (11%) in white males (females) and just 5% (5%) of Chinese 
males (females). Differences in ethnic makeup between cases and controls can 
therefore cause different allele frequencies at some SNPs, and these SNPs may be 
wrongly interpreted as associated with case/control status.  This phenomenon is 
called population stratification.  Genome-wide association studies are usually limited 
to a single population, and sample ethnicity can be verified genetically using 
Principal Components Analysis (PCA) (Price et al., 2006).  More subtle population 
stratification can be adjusted for by including principal components that correlate 
with ethnicity in the genetic model that is used to test for association between 
phenotype and genotype. 
1.3.2.1.5 Heterozygosity 
An individual who is the offspring of unrelated parents from the same population 
should have genotypes in Hardy-Weinberg equilibrium.  Higher than expected 
heterozygosity could be the result of sample contamination, while low 
heterozygosity could indicate that the parents are not from the same population, or 
could indicate an inbred individual.  In any of these cases the unusual distribution of 
genotypes means that these samples should be removed from the analysis. 
1.3.2.2 SNP Quality Control 
SNP quality control aims to identify and/or remove SNPs that were poorly genotyped 
or that may be difficult to analyse.  There is some flexibility in deciding to remove 
SNPs, as it is possible, and indeed recommended, to check quality control metrics for 
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any significantly associated SNPs after association analysis.  SNPs showing strong 
associations but with poor QC metrics can either be ignored or given a low priority 
for replication. 
1.3.2.2.1 SNP missingness 
SNPs with high missingness should be removed from the analysis as this generally 
indicates poor quality genotyping.  As with individual missingness, if DNA quality 
varies with the phenotype then non-random missingness can be mistaken for an 
association signal.  
1.3.2.2.2 Minor allele frequency 
SNPs with low minor allele frequencies (MAF) are often removed from the analysis 
or analysed separately using different methods.  Low MAF SNPs are more sensitive 
to genotype calling errors as there is less information in rare genotypes for the 
clustering algorithm to use.   Low MAF SNPs are also more sensitive to genotyping 
errors or non-random missingness, as small changes in rare groups can have large 
effects.  Power is also reduced at low MAFs, so even when they are analysed it may 
be theoretically impossible, or very difficult, to get a strong enough association 
signal to overcome the required correction for multiple testing. 
1.3.2.2.3 Hardy-Weinberg equilibrium 
Extreme departures from Hardy-Weinberg equilibrium (HWE) can indicate poor 
genotyping.  For example, poor separation in probe signal intensities between the 
three genotype groups can cause the calling algorithms to call only two groups 
instead of three.  False association signals can result if this problem occurs 
preferentially in cases or controls, leading to a large difference in allele frequencies.  
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This is likely to happen more frequently if cases and controls are genotyped 
separately. 
A very strong association signal in a case/control study can also lead to a departure 
from HWE in cases if the underlying risk model is non-multiplicative.  It is therefore 
sensible not to be too stringent with the HWE threshold to prevent removing SNPs 
with a strong true signal or to apply HWE thresholding based on control genotype 
frequencies only.  
1.3.3 Analysis of Association Studies 
After genotype and phenotype data is collected, it now becomes a statistical 
challenge to judge if the two are associated.  The type of phenotype being considered 
will determine the type of analysis carried out to test for association. 
1.3.3.1 Association with Disease Status (Binary Trait) 
1.3.3.1.1 Chi-square (allelic) test 
A popular type of GWAS is the case/control design. People who are affected by a 
certain disease are designated as 'cases', and these are compared to controls who are 
either screened to be unaffected by the disease or an unscreened collection of people.  
We begin with a single SNP.  In this scenario we can compare the presence of the 
two alleles in the populations of cases and controls.  We can create a 2 x 2 




Table 1. Example of a contingency table for applying a chi-square test to a single SNP 
Allele cases controls 
A 100 80 
a 60 55 
 
A simple chi-square test (with 1 degree of freedom) of association can be carried out 
on this table to test the independence of allele frequency and case/control status.   
This is a test for a single locus, and it must be repeated for all loci in the study. 
Hundreds of thousands of tests can be carried out, and this dramatically increases the 
chances of seeing a positive results purely by chance.  To deal with this problem a 
suitable correction for multiple testing must be applied, and this is discussed in 
section 1.3.3.3. 
1.3.3.1.2 Trend Test 
The Cochran-Armitage trend test is a modification of the chi-square test.  Both the 
allelic and Cochran-Armitage tests are tests of a multiplicative allelic risk model, but 
the allelic test requires that the control genotypes be in HWE, while the Cochran-
Armitage test does not so is generally preferred. For this test samples are divided into 




Table 2. Example of a contingency table for applying a trend test to a single SNP 
Allele cases controls 
AA 100 80 
Aa 60 55 
aa 15 8 
 
This is a very popular approach for a fast test of association, and has been used in 
several successful major studies (Wellcome Trust Case Control Consortium, 2007, 
Mells et al., 2011).   
1.3.3.1.3 Logistic regression 
Logistic regression is a more flexible regression modelling approach for binary 
outcomes, which allows additional covariates to be used.  This allows, for example, 
for PC scores from a PCA to be added as covariates.  The model is fit using 
maximum likelihood estimation to estimate coefficient values, as there is no 
analytical solution. Regression coefficients can then be used to determine the effect 
of each coefficient (e.g. a SNP) on the outcome (case/control status).  This is usually 
done by a simple transformation of the coefficients to give odds ratios (the 'risk' of 
being a case given a particular genotype).  An odds ratio is the ratio of the odds of an 
event occurring in one group (e.g. cases) to the odds of it occurring in another group 
(e.g. controls).   
  
Equation 1 gives the form of the logistic regression model. 
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Equation 1. Logistic regression model with covariates 
 
where pi is the probability of sample i being a case, α is a constant coefficient, βs are 
the regression coefficients, x is the genotype data, pc1 is the first principal 
component, and sex is a dichotomous variable indicating the sex. Logistic regression 
is a widely used method in case/control designs, particularly when there are 
covariates to be added to the model (Strange et al., 2010, Evans et al., 2011). 
1.3.3.2 Association with quantitative traits 
Not all phenotypes of interest can be measured as a 2-category (dichotomous) 
outcome as in the case/control study design.  Some phenotypes, such as height, 
weight, or the amount of a particular substance in the blood, are better measured on a 
continuous scale.  If the measurements are normally distributed then we can analyse 
this type of data in a linear regression framework.  The formula to describe this 
relationship is given by: 
Equation 2. Simple linear regression model 𝑦! = 𝛼 + 𝛽𝑥! + 𝜀  
where yi is the quantitative trait for individual i, α is a constant coefficient, xi is the 
SNP allele count for individual i, β is the coefficient for the SNP, and ε is the error 
term. 
1.3.3.2.1 Survival analysis with Cox Proportions Hazards modelling 
Survival analysis is an extension of regression analysis to handle time-to-event data.  
In this scenario the time of the event of interest is recorded and this is used as the 
response.  However it is possible that a subject can be observed over a time period 
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that does not include the event.  Any such observations are considered to be 
'censored' events.  The event could have occurred before observation began (left-
censored) or may not have happened by the time of the latest recorded observation 
(right-censored). In the case of right-censoring, a study could finish or a subject 
could be lost to follow-up before the event occurs.  The last observation time is still 
recorded but the outcome is classified as right-censored.  It is impossible to 
determine if the event would have happened the day after the recorded censoring 
time or many days, months or years in future, so it is not correct to view the censored 
time as an event time.  However there is still value in knowing that the event has not 
happened in the time that has elapsed.  In the data sets I have used for the work in 
this thesis only right-censoring has occurred, and no further reference will be made 
to any other form of censoring or truncation. 
The basic elements used in survival modelling are the survival function and the 
hazard function.  Let T be a continuous random variable with probability density 
function (p.d.f.) f(t) and cumulative density function (c.d.f.) F(t).  For a continuous 
random variable, the c.d.f. is defined as the integral of the p.d.f. 
𝐹 𝑥 = 𝑃𝑟(𝑋 ≤ 𝑥) 𝑓(𝑡)!!!  
 The survival function can be thought of as the probability that the event of interest 
has not occurred by time t, which is the complement of the c.d.f..  
𝑆 𝑡 = Pr 𝑇 > 𝑡 = 1− 𝐹 𝑡 = 𝑓(𝑡)!!  
The hazard function is the probability of the event happening at the current time 
given that it hasn't happened yet.  This is a conditional probability which can be 
defined for discrete and continuous time. For a discrete distribution, the hazard can 
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be calculated at each time point.  For continuous time, the hazard at time t is 
calculated over a time interval (t, t+dt) as the size of the interval (t+dt) approaches 0.  
The probability of the event happening at time t is given by the pdf, while the 
probability of the event not happening until time t (the condition) is given by the 
survivor function.  The hazard function λ(t) is therefore the ratio of these two values. 
ℎ 𝑡 = 𝑓(𝑡)𝑆(𝑡) 
If the hazard rate is constant over time, survival time could be modelled by an 
exponential distribution. However in real data it is likely that the hazard function 
may not be constant over time, and it might not be sensible to assume a underlying 
distribution.  For example, a person's chance of dying might be higher at a very 
young age, then lower as the risk of childhood illnesses falls, then rise again as the 
risk of age-related disease rises.  The Cox proportional hazards model (Cox, 1972) is 
a semi-parametric approach to modelling hazards.  This model is considered semi-
parametric because there is a baseline function which can take any form, but 
variables enter the model in a linear predictor.  The baseline hazard in a Cox model 
also absorbs the constant term which is usually a part of a parametric regression 
model.  The Cox proportional hazards model is: 
Equation 3. Cox proportional hazards model log! ℎ! 𝑡 = 𝛼 𝑡 + 𝛽!𝑥!" 
where ℎ! 𝑡  is the hazard function, 𝛼 𝑡  is the baseline hazard, and 𝛽!𝑥!" is the set 
of n coefficients (ß) for n variables (x) over i subjects.  The baseline hazard is the 
regression constant, which is the value of the hazard function when all of the x's are 
0 (e.g. 𝛼 𝑡 = ℎ! 𝑡 ).  The remainder of the right-hand side (𝛽!𝑥!") is a linear 
predictor for which parameters 𝛽! can be estimated.   
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Estimation of parameters is done by maximising what Cox called the partial 
likelihood function. 
Equation 4. Cox's partial likelihood function 
𝐿! 𝛽 = exp  (𝑥!!𝛽)exp  (𝑥!!! 𝛽)!!!"(!!) !!!!!!  
where R(ti) is the set of subjects at risk (risk set) at time ti (event time for subject i, 
censored or not) and ci is an indicator variable with c=0 for a censored observation 
and c=1 for an event. Censored times enter the likelihood function as part of the risk 
set but are not included in the likelihood as separate terms, as the entire term for 
censored times reduces to 1.  The ratio !"#  (!!!!)!"#  (!!!! !)!!!"(!!)  is the hazard for subject i at 
that subject's event time, relative to all subjects at risk.  
Maximum partial-likelihood estimates share many of the same properties as 
maximum-likelihood estimates, and can be used in likelihood ratio tests.  
1.3.3.3 Correcting for multiple testing 
Statistical tests such as described in section 1.3.3 are usually evaluated at a threshold 
of significance such as 5% or 1%.  Under the null hypothesis of no association, p-
values are uniformly distributed between 0 and 1.  As a result, a threshold of 5% 
means that if the experiment were repeated 100 times, we would expect about 5 of 
the results to have a p-value of 0.05 or below.   In a GWAS we will be carrying out 
not 100, but several hundred thousand tests.  If there are 500 000 SNPs to be tested, 
we would expect 25 000 of these tests to give a 'significant' p-value of 0.05 or less 
even if there are no real associations at all, which is clearly not a desirable outcome.  
It is therefore important to set a very strict threshold, far smaller than 5%, to try to 
ensure that results are real.   
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A commonly used correction for multiple testing is the Bonferroni correction.  This 
involves dividing the desired threshold for significance by the number of tests. In the 
case of a GWAS with 500 000 SNPs, measured at the 5% level of significance, this 
would mean that the Bonferroni-corrected threshold for significance is  
0.05/500 000 = 10-7.   
1.3.4 Important results from Genome-Wide Association Studies  
The first successful genome-wide association study was published in 2005 (Klein et 
al 2005). Researchers genotyped 95 people with age-related macular degeneration 
and 50 healthy controls at 105 098 SNPs after quality control measures were applied.  
This was a fortunate choice of phenotype, as most common variants are of small 
effect size, and would not be detectable with such a small sample size.  This study 
found a SNP in the complement factor H (CFH) gene to be strongly associated with 
AMD (OR=4.6 (heterozygotes) and 7.4 (homozygotes), p=4.1x10-8,).  This SNP was 
intronic and therefore unlikely to be causal. Follow-up sequencing of CFH exons led 
to the discovery of the associated non-synonymous SNP rs1061170.  This SNP is 
still being investigated with mixed findings and varying odds ratios; in particular it 
does not seem to be associated with AMD in non-Caucasians (Sofat et al 2012).  It is 
still unclear whether this variant is causal or if it tags an undiscovered causal variant.  
Since allele frequencies and LD patterns vary between populations, one possibility is 
that that this SNP is in LD with the causal variant in European populations but not 
others, explaining the different findings in non-Caucasions. 
In 2007 the Wellcome Trust Case Control Consortium published an important paper 
on a large-scale GWAS in 7 different diseases.  The sample sizes for these studies 
were much larger, with approximately 2000 cases for each disease.  It was also the 
first study to use shared controls, with a single set of approximately 3000 unscreened 
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population controls.  Association signals were identified in five of the seven 
phenotypes studied, the most successful being Crohn's Disease with 5 associations 
passing a strict Bonferonni-corrected p-value threshold.  This study showed that 
using large sample sizes, strict quality control, appropriate multiple testing correction 
and independent replication could result in success for GWAS. 
Many GWAS have now been carried out, and the resulting associations have been 
collected and summarised into a catalogue of published GWAS by the National 
Human Genome Research Institute (Hindorff et al, 2009).  
 
1.3.5 Epistasis 
The definition of epistasis is complicated and depends somewhat on one's point of 
view (reviewed in (Cordell, 2002)). Biologists and statisticians will almost certainly 
give different definitions, with neither of these likely to be exactly what the people 
who first used the word in the respective fields intended.  Here I will outline several 
definitions of the word and specify how I will use it in this thesis, as well as 
introduce various methods and software packages currently in use for their detection. 
1.3.5.1 Measuring Epistasis 
A definition of biological epistasis was first given by Bateson in 1909 (Bateson, 
1909).  He examined a family of rabbits that carried a gene for albinism.  He 
describes two pairs of 'allomorphs' (alleles), one of which determines grey/black 
colour and the other determines colour/albinism.  He noted that "The presence of one 
or other determiners G or B is only perceptible when it exists in combination with 
the colour-factor". 
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After explaining all of the possible combinations of alleles and their outcomes, he 
goes on to introduce new terms to describe this relationship: 
"Pending a more precise knowledge of this relationship it will be enough to regard 
those factors which prevent others from manifesting their effects as higher, and the 
concealed factors as lower.  In accordance with this suggestion the terms epistatic 
and hypostatic may conveniently be introduced."   
The term epistasis continues to be used today, although the term hypostatic is no 
longer in common use.  Bateson's use of the term epistatic to refer only to the effect 
of the 'higher', or masking, factor is rarely used now, and instead the term epistasis 
usually refers to the general situation in which one gene modifies the expression of 
another gene.  
The word epistasis is now also commonly used in quantitative genetics, and was 
described in this sense by Ronald Fisher (Fisher, 1918).  He described epistasis: 
We may say that the somatic effects of identical genetic changes are not additive, 
and for this reason the genetic similarity of relations is partly obscured in the 
statistical aggregate. A similar deviation from the addition of superimposed effects 
may occur between different Mendelian factors. We may use the term Epistacy to 
describe such deviation, which although potentially more complicated, has similar 
statistical effects to dominance. 
This is a rather long-winded way of saying that epistasis is the deviation of effects 
from the additive linear model.  In section 1.3.3 the analysis of genetic data using a 
linear model is described.  This model includes only 'main' effect terms; that is, the 
effects of each term in the model act independently. The direction and size of effect 
due to one term in the model do not depend on the value of any other terms in the 
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model.  When this is not the case, including non-linear terms such as interactions in 
the model may better explain the relationship between genotypes and phenotypes.  In 
the simplest two-locus case, we can look at counts of cases and controls across the 
two loci and visualise a non-linear relationship. Figure 1 shows the effect of carrying 
different alleles at two loci, A and B.  The effect of the alleles carried at locus B 
varies depending on the alleles carried at locus A.  People who have the AA 
genotype at locus A have no increased risk regardless of the genotype at B. However 
if a person carries one copy of the "a" allele then risk increases depending on the 
number of "b" alleles carried at locus B.  This effect is even greater in those carrying 
two copies of the "a" allele. 
 
Figure 1. Two-locus interaction effect 
Modelling this mathematically would require a non-linear term to describe the 
interaction between two effects, such as in Equation 5. 
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where yi is the response for individual i, β1 and β2 are the coefficients for the two 
variables x1 and x2, β3 is the coefficient for the interaction between x1 and x2, and ε is 
the error term.   
For the remainder of this thesis, the use of the word 'epistasis' will be restricted to the 
statistical definition above unless otherwise indicated.  Furthermore, the terms 
"genetic interaction" and "gene-gene interaction" will be used synonymously with 
epistasis. 
1.3.5.2 Interactions in Genome-Wide Association Studies 
The hypothesis that groups of SNPs act together to affect a phenotype is a plausible 
one.  It sounds reasonable biologically that a disease or a physical trait could be 
determined by a group of polymorphisms rather than just one.  
There has been interest in detecting epistatic effects in GWAS data. These are widely 
presumed to exist (Zuk et al., 2012), and finding these would constitute an important 
source of extra information from our GWAS studies. There are many reasons why 
finding these effects in GWAS data is challenging, (1) the search space grows 
exponentially as we increase the number of SNPs, (2) power is reduced due to the 
increase in degrees of freedom arising in a model with interaction terms (particularly 
if the full genotypic model is used) and (3) poor tagging of causal SNPs has a greater 
effect on the power to detect higher-order interactions than main effects (Reimherr 
and Nicolae, 2011).  
There have been few examples of statistical interactions between SNPs in a GWAS 
that have been successfully replicated in an independent cohort. Recent studies into 
psoriasis and ankylosing spondylitis, two immunological diseases, both discovered 
interactions between a SNP in ERAP1 and a SNP in the major histo-compatibility 
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(MHC) region on chromosome 6.  The study in psoriasis (Strange et al., 2010) 
discovered an interaction between SNPs in ERAP-1 and HLA-C genes, and this was 
confirmed in their replication cohort.  The study in ankylosing spondylitis (Evans et 
al., 2011) found an interaction between ERAP-1 and HLA-B, and this also 
replicated.  In each case these interactions were found by taking all SNPs which 
showed genome-wide single-SNP association signals and testing for interactions 
between all possible pairs.  The replication of each of these findings within their 
studies, and the similar findings in two immunological diseases, make these the most 
convincing interactions found to date in a GWAS. 
1.3.5.3 Current Methods and Software for Interaction Testing 
It is now computationally feasible to analyse all pairwise interactions in a GWAS 
(Marchini et al., 2005). However this approach requires significant computing power 
and is impractical if not impossible for higher-order interaction effects.  Several 
more efficient methods have been suggested for searching for interactions in GWAS 
data (reviewed by Motsinger-Reif et al., 2008, Cordell, 2009).  Many require some 
form of pre-screening to limit the number of interactions that need to be analysed, 
which usually involves the selection of SNPs based on single-SNP association p-
values.  This makes interaction testing quicker and easier but may miss interactions 
in which one or both SNPs lack a strong marginal effect. Here I will describe some 
of the popular methods and software packages and highlight their strengths and 
weaknesses.  Chapter 2 of this thesis will describe a comparison of a selection of 
these methods for detecting epistasis in GWAS, with a focus on finding a software 
package that can efficiently analyse whole-genome data without a pre-screening step.   
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The software package PLINK (Purcell et al, 2007) has two options to test for 
interactions.  The first fits a full logistic or linear model including an interaction term 
and tests if the coefficient of the interaction is equal to zero.  The second is a faster, 
approximate test for case/control designs only. First the data is divided into cases and 
controls and odds ratios are calculated for a pair of loci in each group. Next a z-score 
is calculated for the difference between the odds ratios in cases and controls.  A 
significant difference means that cases and controls carry different combinations of 
alleles across the two loci, and this may indicate epistasis.  
 
Tree-based Epistasis Association Mapping (TEAM) uses a "minimum spanning tree 
structure", which involves building a contingency table for two SNPs. The table is  
pared down to utilise only those cells with different genotypes between the two 
SNPs. Removing the unnecessary samples reduces computation time and speeds up 
the analysis, however this method still doesn't scale well and can't be run on genome-
wide data.  
 
Multifactor Dimensionality Reduction (MDR) (Ritchie et al 2001) takes high-
dimensional SNP data and reduces it to a single dimension by allocating each multi-
locus genotype to high-risk or low-risk categories.  The single-dimensional model is 
then used to predict disease status.   Although popular, MDR does not scale up well 
to large numbers of SNPs such as from a GWAS and would therefore require a pre-
screening step to run on GWAS data. 
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Bayesian Epistasis Association Mapping (BEAM) (Zhang et al, 2007) implements an 
MCMC simulation algorithm to estimate posterior probabilities for each SNP's 
membership in three groups - SNPs with no effect, SNPs with main effects only and 
SNPs which interact.  As with many Bayesian simulation methods, BEAM is slow 
and it does not scale up to the number of SNPs measured in a GWAS.  
 
Various penalized regression models have been applied to GWAS data to attempt to 
build stable models with large numbers of predictors using relatively small sample 
sizes.  Although these methods can in theory fit parameters to high-dimensional data, 
they do not scale up to the number of parameters that would need to be modelled for 
a full pairwise interaction analysis using GWAS data. 
 
INTERSNP is a software package which implements several possible screening steps 
to reduce the number of SNPs for analysis. This is followed by a choice of 
interaction analysis tools including parametric and non-parametric methods.  
Although this software can handle genome-wide data as input, it does so by first 
screening out some of the data before applying the interaction tests. 
 
Since carrying out the work described in this chapter, further methods and software 
packages have been released that can be applied to GWAS data without a screening 
step.  EpiBlaster (Kam-Tong et al 2011) uses a two-stage method.  The first stage 
screens using a fast but lenient method, allowing strong interactions to affect the 
ranking of SNPs.  Stage two specifically models interaction effects for SNPs passing 
stage one. Epiblaster is also implemented for use on graphical processing units 
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(GPUs) which can perform high-speed parallel processing on a single processor.  
BiForce (Gyenesai et al 2012) is a recently published software package which uses 
efficient storage structures, fast operations and parallelization to accelerate pairwise 
analysis.  SIXPAC (Prabhu et al, 2012) is one of the fastest software packages for 
detecting epistasis in GWAS data, using ROC curve analysis as a first-stage screen 
which allows for interaction effects.  EpiBlaster, BiForce and SIXPAC were not 
available at the time of carrying out the work in Chapter 2, but may be sensible 
current choices for detecting epistatic effects in GWAS data. 
 
Random Jungle (Schwartz et al) is a fast implementation of the Random Forest 
algorithm (Breiman et al).  Multiple binary trees are created by splitting data 
recursively.  At each split point the data is divided by genotypes to produce new 
groups which maximise cases in one group and controls in the other. The stochastic 
element is introduced in two ways; limiting the samples available to build each tree 
and having only a subset of SNPs available at each split point.  Random Jungle is 
fast and was built specifically to be used on GWAS data. 
 
SNPHarvester is a heuristic hill-climbing algorithm which is guaranteed to find local 
maxima, but will not necessarily find the best global solution. Random SNP groups 
are selected to start the hill-climb, and new SNPs are tested one at a time for 
improved scores for association of the SNP group with the phenotype.  This process 
is repeated many times, and SNP groups whose scores exceed a user-defined 
threshold are saved for follow-up. Longer run-times will search more thoroughly and 
increase the probability of finding the global maxima or significant local maxima. 
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Sparse Partitioning, in its original format, is a Bayesian method for identifying sets 
of predictors associated with a response.  It also explores all possible 'partitions' of 
those predictors, where a partition is a group of predictors jointly affecting the 
response.  In this way, single-SNP and interactions of an order up to a user-defined 
limit are explored at the same time and without assumptions about genetic 
architecture, making this an attractive option for exploring GWAS data. As with 
many Bayesian solutions it does not scale up to whole-genome data, but there is an 
alternate implementation using a deterministic approach which makes analysing 
GWAS data computationally feasible. 
In Chapter 3 I describe work on comparing three methods for testing interactions, 
using a real data set with a replicated interaction effect as a positive control.  I 
selected methods primarily based on their ability to process genome-wide data 
without a pre-screening step, to allow for the possibility of interaction effects in the 
absence of marginal effects.  Ideally my optimal method should be able to efficiently 
search as much of the interaction search-space as possible, with reasonable power to 
detect interactions in typical genome-wide association studies. 
 
1.3.6 Heritability 
Variability in a trait between individuals is attributable to genetic and environmental 
effects.  The heritability of a trait is defined as the proportion of total variance in the 
trait explained by genetics.  Heritability of traits or medical conditions is usually 
calculated by analysing sets of twins. Twins may be monozygotic (sharing 100% of 
their DNA) or dizygotic (sharing 50% of their DNA).  Because twins are likely to 
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share a large part of their environment, we can assume that differences in prevalence 
between mono- and dizygotic twins of affected individuals are due solely to 
differences in genetic makeup.  This allows us to estimate heritability as a 
percentage.  For example, a disease that is 30% heritable means that 30% of a 
person's risk of developing a disease is attributed to their genetic makeup, while the 
remainder is due to environmental factors.  Examples of possible environmental 
factors contributing to disease risk are diet, smoking, urban vs rural environment and 
exposure to toxins. 
Genome-wide association studies to date have successfully discovered many loci 
associated with diseases in case/control studies.  However the amount of variability 
explained due to these associated variants is usually not anywhere near the 
heritability as estimated in twin studies (Maher, 2008).  It does seem likely that a 
complex organism such as a human being will have a complex genetic architecture, 
with many genes working together to produce measurable phenotypes.  Interactions 
between genetic variants have therefore been suggested as one possible contributor 
to missing heritability in complex genetic traits and diseases.  
1.4 Kidneys, Renal Failure and Transplantation 
Our kidneys are a key part of the urinary system, and their functions are essential to 
our health.  The kidneys are responsible for many functions such as filtering the 
blood by removing certain toxins and excreting them as waste,  maintaining blood 
pressure through balancing salt and water in the blood,  reabsorbing water and some 
nutrients and producing some hormones and enzymes. 
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1.4.1 Kidney Failure and Dialysis 
Around 1 in 10 people have some degree of chronic kidney disease (CKD) (British 
Kidney Patient Association, 2012b). CKD is a descriptive term for kidneys with 
long-term poor function.  CKD is not a disease itself; it is usually a response to an 
underlying condition, and can sometimes be reversed depending on the cause.  If 
renal function deteriorates beyond a certain point then the person has 'end-stage renal 
failure' (ESRF), and renal replacement therapy is indicated.  Approximately 10% of 
people with CKD progress to renal failure.  Some of the common underlying causes 
of renal failure are diabetes, high blood pressure and polycystic kidney disease. 
People with the above conditions are not all on the transplant list; treatment can 
maintain or improve renal function in some cases.   
In some situations a kidney can suffer acute damage (British Kidney Patient 
Association, 2012a).  Acute renal failure is often temporary.  It can be caused by loss 
of blood supply to the kidney (for example, due to low blood volume after an injury), 
toxins or obstruction of the urinary tract.  If the underlying cause can be treated 
successfully then kidney function may return.  However permanent kidney damage is 
a possibility, in which case the individual can have end-stage renal failure. 
Once a person is in ESRF the patient must receive some form of renal replacement 
therapy, or the build up of toxins and the imbalance of fluids and salts in the body 
can be fatal.  Patients may undergo dialysis, which involves mechanically and 
chemically filtering the blood.   
Traditional haemodialysis involves visiting the hospital up to three times per week 
and having a large volume of blood removed, filtered and returned to the body 
(British Kidney Patient Association, 2012c).  It usually involves the insertion of a 
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catheter or construction of a fistula, both of which can be painful and inconvenient.  
Home dialysis is sometimes possible but involves a significant amount of training 
and a person to help with the home dialysis. 
Peritoneal dialysis (British Kidney Patient Association, 2012d) can be done at night 
(automated peritoneal dialysis, or APD) or during the day (continuous ambulatory 
peritoneal dialysis, or CAPD).  The lining of the abdomen, or the peritoneum, acts in 
place of the kidney. Fluid is introduced into the peritoneal cavity and sits for several 
hours. Waste products pass from the peritoneum into the fluid, then the fluid, with 
the waste, is drained away.  This process can be carried by the patient out at home, or 
in any clean environment with the right equipment.  This option may allow the 
patient more freedom than traditional haemodialysis. 
The aim of dialysis is to keep the patient alive, but there are side effects and risks to 
consider.  Patients may suffer from side effects such as tiredness, nausea, loss of 
appetite and depression.  A dialysis patient's fluid intake and diet needs to be tightly 
controlled.  There is a risk of infections at the catheter insertion site or fistula (in 
haemodialysis), or the peritoneum (in peritoneal dialysis).  
1.4.2 Kidney transplantation and the UK Transplant Waiting List 
A patient with end-stage renal failure will usually be put on the transplant waiting 
list.  If a transplant is possible, the outcome is generally far better than long-term 
dialysis.  While dialysis can keep a patient alive, a transplant can restore renal 
function and with it a person can return to full fitness.  A transplant itself is not 
without risk but the long-term prognosis is much better than staying on dialysis. A 
large American study of patients on long-term dialysis for end-stage renal failure 
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found that the long-term mortality risk for transplant recipients was 68% lower than 
that of patients on the waiting list (Wolfe et al., 1999).   
Ninety per cent of people on the UK's transplant waiting list are waiting for a kidney.  
The number of people currently waiting for a kidney is about 7000, yet only 2 500 
transplants are carried out each year (Johnson et al., 2010).  Transplanted grafts do 
not necessarily last for the lifetime of the patient, and when the kidney fails the 
recipient will have to go back on the transplant waiting list and back on dialysis 
while waiting for a new kidney.  A recent large study of transplants involving 
deceased donors (Wolfe et al., 1999) found that death-censored graft survival at 5 
years was 85.1% for cardiac-death donors and 83.2% for brain-death donors.  
Another recent study of deceased-donor transplants (Watson et al., 2012) found that 
5-year graft survival was 76.7-83.1% after stratification by a number of risk factors.   
The most recent report from NHS Blood and Transplant (the organisation which 
maintains a database on all UK transplants) found five-year graft survival following 
cadaveric donor transplantation to be 79-83% for brain death donors and 73-85% for 
cardiac death donors, while ten-year survival was 67% for both groups. 
These patients whose transplants fail will go back on the transplant waiting list, 
creating more demand for a very limited resource. 
1.4.3 Factors Affecting Long-Term Transplant Outcome 
Before discussing the impact of various clinical factors on transplantation, there are 
several key terms relating to transplantation that need to be defined: 
A graft is a term for living tissue that has been transplanted. An allograft is any 
transplanted tissue that is from a source that is not genetically identical (e.g. not from 
self or identical twin). 
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A heart-beating donor (HBD) has suffered brain death but is kept alive on life 
support until organs are removed for transplantation.  Circulation is maintained until 
the time of organ harvesting. A non-heart-beating donor (NHBD) is not sustained on 
life support at the time of organ harvesting; they have already experienced cardiac 
death.  They may be brought to hospital already deceased, they may have had cardio-
pulmonary resuscitation on the way to or at the hospital, or they may undergo cardiac 
death in hospital after the withdrawal of life support, but before organs are 
transplanted.  
Cold ischaemic time is the time between the removal of a kidney from a donor and 
the time blood flow is restored to the kidney after transplantation in the recipient. 
HLA type - The current nomenclature for HLA typing describes the alleles a person 
carries in the HLA genes.  The type for each protein is preceded by the locus name 
(e.g. "HLAC") and followed by an even number of digits which come in pairs.  The 
type can be of variable 'depth', with the shallowest description containing 2 digits 
that describe a broad molecular type which groups many alleles together.  As 
technology has advanced, more specific typing has become possible and further pairs 
of digits (up to 4 pairs in total) now identify HLA type sub-groups more specifically.  
Kidney donors and recipients in the past have been matched as closely as possible by 
HLA type as rejection of the organ was less likely.  More recently, better 
immunosuppressive drugs have meant that poor HLA matching can still lead to a 
good transplant outcome, and this is becoming more common (Johnson et al., 2010). 
Serum creatinine is used as a biomarker for kidney function.  Creatinine is produced 
by muscles and is filtered out of the blood by the kidneys.  High creatinine levels 
indicate poor kidney function.  Creatinine levels that do not come down after 
transplantation or that rise sharply in a transplant recipient may indicate an episode 
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of acute rejection.  Creatinine levels that rise slowly over time may indicate chronic 
rejection. 
Acute rejection is caused by an immune system response to the transplanted organ.  
It is usually suspected when a recipient's serum creatinine rises sharply, usually 
within the first year of transplantation.  It can usually be treated with a strong dose of 
immunosuppressants and kidney function may return to normal after an acute 
rejection episode, though it doesn't always. 
Chronic rejection (also known as chronic allograft nephropathy) is a slow process 
which results in damage to the kidney and may eventually lead the graft to fail.  A 
change in the long-term immunosuppressive regime may slow or stop graft 
deterioration but this is not always possible. 
1.4.3.1 Clinical Factors 
An understanding of factors affecting the graft survival time for a kidney transplant 
may be a useful first step in relieving the pressure on the transplant list.  Matching 
donors and recipients as well as possible may help prolong the life of a graft, which 
will mean less people returning to the waiting list.  Much work has been carried out 
to identify clinical factors in both donors and recipients that may affect the long-term 
prognosis of the transplanted graft.  A recent UK study into the effect of heart-
beating vs non-heart-beating donors (Summers et al., 2010) in kidney transplants 
found no differences in survival between the two groups. Within the non-heart-
beating group, they also showed that increasing age of donor and recipient; repeat 
transplantation and longer cold ischaemic time were associated with worse graft 
survival, while poor HLA matching had a negative but not significant effect.  A 
similar study involving deceased heart-beating donors (Johnson et al., 2010) found 
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older donor and recipient age, waiting time to transplant over 2 years diabetes and 
earlier year of transplant, HLA mismatching and cold ischaemic time were 
associated with poorer graft survival over 5 years.  
1.4.3.2 Genetic Factors 
 Few genetic studies have been carried out in renal transplantation in relation to graft 
survival time.  Genetic studies in transplantation to date have tended to focus on 
prediction of rejection using biomarkers, or analysis of gene expression data rather 
than single-nucleotide polymorphisms.  Some genetic studies have also been carried 
out in renal failure in the absence of transplantation.  No genome-wide association 
studies involving donors and recipients have been published in renal transplantation 
to date.  Those genetic studies of polymorphisms in transplantation that have been 
carried out have been candidate gene studies, which have met with mixed success.  
Candidate gene studies have many challenges that make finding convincing results 
difficult.  According to Ioannidis et al (Ioannidis, 2005): 
"...a research finding is less likely to be true when the studies conducted in a field 
are smaller; when effect sizes are smaller; when there is a greater number and lesser 
pre-selection of tested relationships; where there is greater flexibility in designs, 
definitions, outcomes, and analytical modes; when there is greater financial and 
other interest and prejudice; and when more teams are involved in a scientific field 
in chase of statistical significance." 
It could be argued that all of these are true to some extent in many candidate gene 
studies.  Small studies and small effect sizes are particularly prevalent in candidate 
gene studies, and both of these problems mean that published findings are more 
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likely to be false positives.  For any particular outcome (such as a phenotype in a 
genetic study), the theory is this: 
1. The pool of non-associated variants is very large, but a small proportion of 
these will wrongly be found to be associated by chance (false positives). This 
proportion is not affected by the power of the study to detect true 
associations.  
2. The pool of true associations is probably very small, and the proportion of 
these that are found depends on the power to detect them. Power in candidate 
gene studies is often hampered by low sample size and small effect sizes, 
meaning few true associations will be found.  
3. As the power to detect true effects decreases and the number of false 
positives remains constant, the proportion of false positives will be higher in 
the total pool of significant results, and these are the results that are likely to 
be published.  
In short, it is likely that at least some low-powered studies that report significant 
findings are reporting false positives.  Correcting for multiple testing (section 
1.3.3.3) is essential and will certainly improve, but not eliminate, this situation.   
In spite of the drawbacks outlined above, I will review the findings from genetic 
studies in renal transplantation bearing in mind that some results may be false 
positives, This may explain why many of these results are only published once, or 
subsequent studies have different findings. 
Lee et al (Lee et al, 2012) looked at the APOL1 gene, which had previously been 
associated with kidney disease in African Americans (Genovese et al., 2010, Tzur et 
al., 2010), and did not find any association with graft survival time after 
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transplantation, although the study was limited to 119 African American recipients.  
The variants found in the African American studies are not present in European 
populations. 
Wahrmann et al (Wahrmann et al., 2011) determined gene copy number variation of 
C4 (a component of the complement system) for donors and recipients in kidney 
transplants, hypothesizing that complement could play a role in graft survival. 
However they did not find any associations of C4 copy number with graft survival or 
any other unfavourable outcomes.  
 Winkelmayer et al (Winkelmayer et al., 2004) looked at three SNPs in the 
methylenetetrahydrofolate reductase (MTHFR) gene and found that certain genotype 
combinations across these loci were more frequent than expected by chance in 
recipients of kidney transplants who had stable graft function. These genotypes were 
not tested for differences in survival time. 
Several candidate gene studies have been carried out on polymorphisms in genes 
coding for cytokines.  
In one study of 199 transplant recipients, a variant in the IL-6 gene was associated 
with 5-year survival (Kocierz et al., 2011). Another study of the same variant in 335 
recipients showed no association (Sánchez-Velasco et al., 2010).  
Müller-Steinhardt et al (Müller-Steinhardt et al., 2004) genotyped recipients at 3 
SNPs (including the previously-mentioned IL-6 variant) and analysed the resulting 5 
haplotypes that existed in their samples across these loci.  They discovered a 
common haplotype (GGG/GGG, frequency 28.5%) with an increased 3-year survival 
rate (95.6% vs 67.3 for all other haplotypes, p = 0.0003 for the log-rank test), which 
remained strong (p=0.006) after accounting for non-genetic covariates (presence of 
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antibodies, HLA-matching, year of transplantation, acute rejection, age and sex of 
donors and recipients).  A follow-up study (Müller-Steinhardt et al., 2007) by the 
same group found that this haplotype was associated with lower IL-6 secretion in 
healthy individuals. A further study (Schulte et al., 2011) in potential kidney 
transplant recipients who were haemodialysed showed no impairment of IL-6 
production in GGG/GGG individuals, though IL-6 production in the haemodialysed 
individuals was already significantly lower than in healthy controls. 
In summary, candidate gene studies have been carried out but have shown mixed, 
mainly unconvincing results in searching for polymorphisms associated with long-
term graft survival, though there may be some evidence of association near the IL-6 
gene.  To date there have been no published genome-wide association studies of 
donors and recipients in kidney transplantation.  
1.4.4 Kidney Transplantation - Two Genomes in One 
Transplantation creates a unique situation in which tissues with two different 
genomes exist in one body.  The only other situation where this is likely to occur is 
between a mother and foetus during pregnancy.  The presence of 'foreign' tissue in 
the recipient is likely to be a contributing factor in graft rejection, and so it is 
particularly interesting to consider the relationship between the two genomes.  
Variants in the recipient, the donor graft, or interactions between the two could 
conceivably affect the survival time of the graft, and searching for these interactions 
is one of the aims of this thesis. 
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1.5 Project Aims and Thesis Outline 
The main aim of my PhD project is to search for statistical interactions in genome-
wide association studies, particularly with reference to a study in renal 
transplantation.   
To explore the nature of these interactions, I began my PhD with a project to search 
for interactions in GWAS data between SNPs in genes that coded for previously 
published protein-protein interactions.  The hypothesis was that, for a given 
phenotype, these SNPs may be enriched for interaction signals compared to random 
SNP pairs throughout the genome.  To explore this idea I wrote a permutation-based 
software package called PERSI (PErmutations analysis for Statistical Interactions), 
which I then applied to a WTCCC study in Crohn's disease. 
I carried out a methods comparison in order to assess existing methods designed to 
search for statistical interactions in case/control GWAS studies.  Many methods 
exist, and many have been evaluated and compared using simulated data. The recent 
discovery of the statistical interaction in a psoriasis GWAS (Strange et al., 2010) 
provided me with a useful positive control to allow me to test promising methods on 
a real data set.  
Throughout my PhD I was involved in two studies in renal transplantation; a GWAS 
carried out at King's College London (KCL) and the WTCCC3 study in renal 
transplant dysfunction (RTD).  The WTCCC3 RTD project was an expansion on the 
initial KCL study, and includes the data from this study.  The main outcome of 
interest for these studies is the survival time of the transplanted kidney, and I was 
particularly interested in finding interactions that may influence this.  This is a 
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particularly interesting problem due to each transplant involving two genomes - the 
donor and recipient. 
1.5.1 Outline of the Remainder of this Thesis  
Chapter 2. Searching for genetic interactions in psoriasis.   
I have carried out a methods comparison of Random Jungle, SNPHarvester & Sparse 
Partitioning, using the HyperLasso method as a post-processing step for 
SNPHarvester and Random Jungle. I have applied these methods to real data from a 
psoriasis study (Strange et al 2011).  This chapter will present the theory, software 
descriptions and findings of this study. 
Chapter 3. Searching for Evidence of Genetic Interactions in Protein-Protein 
Interactions.   
This chapter will present the theory, software implementation and findings of a study 
looking for an enrichment of low p-values between SNPs in genes coding for 
proteins involved in reported protein-protein interactions.    
Chapter 4. Genome-wide association study in renal transplantation.  
This chapter will outline my contribution to this study, including work on quality 
control and several case/control analyses  
Chapter 5. Wellcome Trust Case Control Consortium (phase 3) study in renal 
transplant dysfunction.  
In this chapter I describe my work on this large collaborative study, including quality 
control, case-control analyses of several secondary phenotypes, and survival 
analysis.  I apply the best method from the psoriasis methods comparison study to 
this data to search for interactions.  I will also present my work on the development 
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of the selected method from the methods comparison, expanding it to take survival 
data by implementing a log-rank function for time-to-event data. 
Chapter 6. Discussion and Conclusions 
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2 Searching for Genetic Interactions in Psoriasis - a 
Methods Comparison 
2.1 Introduction 
Psoriasis is a complex immunological disease that has been the subject of a number 
of genetic studies.  Several loci were found to be associated with psoriasis from 
linkage studies (reviewed in Elder et al 1994, Trembath et al 1997, Nair et al 1997).  
Genome-wide association studies narrowed the search and identified new loci 
(Cargill et al 2007, Nair et al 2009, Zhang et al 2009).  In 2010 the Genetic Analysis 
of Psoriasis (GAP) consortium and the Wellcome Trust Case Control Consortium 
(phase 2) published the results of a large GWAS (Strange et al 2010), which 
replicated 9 previously-identified loci.  They also discovered 8 new loci and 
replicated these in an independent cohort.  All pair-wise interactions between these 
17 loci were tested using logistic regression modelling, and an interaction between 
SNPs rs10484554 (HLA-C) and rs27524 (ERAP1) showed a significant interaction 
effect (p=2.45*10-5, replication p=0.027, combined p=6.95*10-6).   
2.2 WTCCC2 Data  
As part of the Wellcome Trust Case Control Consortium phase 2 (WTCCC2) 
psoriasis study, 2178 psoriasis cases were genotyped on the Illumina Human660W-
Quad chip and compared to 5175 common controls genotyped on the Illumina 
custom Human1.2M-Duo platform (Strange et al., 2010).  Analysis was performed 
on the overlapping set of 535475 SNPs after quality control filters were applied.  An 
initial single-snp analysis replicated 9 previously-identified loci and 8 new loci and 
replicated these in an independent cohort.  These association signals were found 
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using Cochran-Armitage trend tests (see glossary) which test the association of the 
number of alleles carried (0, 1 or 2) with case/control status, taking into account the 
direction of effect.  For example a strong signal may be detected for a SNP that has 
few cases with no risk alleles, more cases with one copy of the risk allele and the 
most cases with two copies of the risk allele.  
Strange et al used a single PC axis to control for population stratification, and I used 
the same PC axis (PC1) in all of my analyses. Strange et al. checked for interactions 
between all of the SNPs whose single-SNP association p-values were smaller than 
the Bonferroni-corrected threshold for genome-wide significance.  An interaction 
was found between SNPs in the HLA-C gene in the Major Histo-compatibility 
Complex region (MHC region) on chromosome 6 and the ERAP1 gene on 
chromosome 5.  The interaction was replicated in an independent set of cases and 
controls.  This confirmed interaction will act as a positive control in my study.  
2.3 Methods 
In the Introduction to this thesis I described several methods that have been 
developed to test for interaction effects between SNPs in GWAS data. The aim of 
this piece of work was to evaluate methods that can search the entire set of GWAS 
data without resorting to screening the data to reduce the search space.  This lead me 
to select three software packages which could run on full GWAS data sets with the 
computing hardware available to me at the time of carrying out the work. Since this 
work was carried out, several software packages have been released which use the 
power of graphics processing units (GPUs) to speed up analysis.  Programmable 
GPUs are now more widely available, and their use may make some of the slower 
methods and programs applicable to GWAS data. 
 64 
2.3.1 Random Jungle 
Random Jungle (Schwarz et al., 2010) is a fast implementation of the Random Forest 
algorithm (Breiman et al), which is a method based on the binary decision tree. 
Random Forests is an ensemble method, meaning many trees are built on 
bootstrapped samples, or samples of the same size taken with replacement. 
This creates many decorrelated trees, and averaging across these trees provides better 
prediction than a single tree.  Bootstrap sampling leaves approximately 1/3 of the 
samples out of each tree ("out-of-bag" or OOB samples), and these OOB samples 
can be used to calculate prediction accuracy. 
Each tree in Random Forests is formed by recursively splitting the data in two to 
decrease an impurity measure in each of the two new "daughter" nodes.  The change 
in impurity measure is calculated by: 
Equation 6. Change in node impurity 
 
where pleft and pright are the proportion of samples in the left and right daughter nodes, 
respectively, and inode is the Gini Index for that node. The Gini index is a commonly 
used measure of homogeneity (see glossary for formula). 
Since our SNPs have three classes, there are different ways in which a SNP can be 
used to split data into two groups.  The algorithm chooses the best binary split after 
either grouping heterozygotes with the major homozygote class or with the minor 
homozygote class.  Resulting daughter nodes are then further split in the same way to 
increase purity. Nodes are split this way down through the tree until terminal nodes 
are 100% pure. Once classification trees are grown they can be 'pruned' back to the 
Δi = iparent − (pleft * ileft + pright * iright )
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point at which the splits significantly improve classification, but this is not done in 
Random Forests; trees are left fully grown, with pure terminal nodes. 
A randomly-determined subset of SNPs is available at each node for selection as the 
split variable. The size m of the available subset is determined empirically to reduce 
classification error in the out-of-bag samples, as suggested by Schwartz et al.  The 
size is held constant throughout the procedure, while a new subset is chosen at every 
node.   
I calculated variable importance measures (VIMs) using the Meng score (Meng et 
al., 2009).  First, OOB samples for every tree are classified using their real 
genotypes. The genotypes for a single SNP are then permuted and the samples 
reclassified.  The Meng score for a SNP is based on the classification of the OOB 
samples using the real genotypes and the permuted data for that SNP, as shown in 
Equation 7.  
Equation 7. Meng score for Variable Importance Measure (VIM) 
𝐼!! 𝐴 = 2𝑇! 1𝑁! [1 𝑉! 𝑋! = 𝑦! − 1 𝑉! 𝑋!(!,!) = 𝑦! ]𝑡!"!!!!
!!
!!!  
IT'(A) - importance measure for SNP A over all T trees, as given by Meng 
Tv - number of trees containing SNP A 
N - number of samples 
Vj(Xi)) - classification of SNP A by tree j using genotype data X from all i individuals 
yi - true class of SNP A 
Vj(Xi)(A,j)) - classification of SNP A by tree j using SNP data from all i individuals, 
with SNP A genotypes permuted  
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The first term in parentheses will be one if classification using all genotypes is 
correct, and zero if it is incorrect.  The second term reduces in the same way but 
using the permuted data for SNP A and real genotype data for all other SNPs.  IT'(A) 
will reduce to approximately 1 if classification is perfect with SNP A and completely 
random when SNP A is permuted.  This is perfect a Mendelian trait with 100% 
penetrance; it is unlikely that a genome-wide association study would be carried out 
on such a phenotype, so Meng scores are not likely to be as high as 1.  IT'(A) will 
reduce to approximately 0 if real and permuted values for SNP A lead to the same 
classification; that is, SNP A is not associated with case/control status, so 
classification depends on all other SNPs.  Most negative numbers will be small, 
being the result of slightly more correct classifications using permuted SNP A data 
than real SNP A data.  Larger negative numbers would indicate systematically better 
classification when SNP A is permuted than when it is not, which is unlikely. 
Previous studies (Nicodemus et al., 2007) have shown that VIMs are unstable and 
best estimates are given by averaging over as many trees as possible.  I set Random 
Jungle to produce 500 forests of 500 trees each, and the median VIM was used 
across all trees to rank SNPs. 
2.3.2 SNPHarvester 
SNPHarvester (Yang et al., 2009) is a stochastic, hill-climbing algorithm designed to 
search efficiently through the space of all possible groups of SNPs.  In this study I 
specified groups of size 2, thereby limiting ourselves to searching for pairwise 
interactions.   
SNPHarvester does a 'first pass' at the data which removes any individual SNPs with 
large marginal effects based on a chi-square test of a full 2-d.f. genotypic model, 
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using a Bonferroni significance correction for all SNPs tested.  These SNPs are 
removed from further analysis, on the assumption that they are easy to identify and 
can be investigated and tested for interactions without the need for sophisticated 
methods.  The PathSeeker algorithm, which is the basis of SNPHarvester, then 
randomly selects a pair of SNPs and carries out a score test.  For a case/control 
design this is a genotypic chi-square test (8 d.f.) of association with disease status.  
The algorithm then cycles through the rest of the data one SNP at a time, checking to 
see if the new SNP can replace one of the current SNPs to improve the score.  If it 
does, the new SNP becomes part of the current group and the old SNP is removed.  
When all SNPs have been considered, if there have been any replacements then the 
cycle is repeated, again retaining any SNPs which improve the score.  When the 
algorithm reaches the end of the data without replacing any SNPs then it has reached 
a local maximum.  Any SNPs which exceed the score threshold (8-d.f. χ2 values after 
Bonferroni significance correction for all possible SNP pairs) are considered 
significant and removed from the search space for future PathSeeker runs. The 
algorithm then begins again with a new randomly-selected pair of SNPs.  PathSeeker 
runs until a pre-specified stopping rule is reached; I set SNPHarvester to stop when 
PathSeeker ran for 15 iterations without finding any new significant pairs.  Figure 1 




Figure 2. The PathSeeker algorithm 
2.3.3 Post-processing with the HyperLasso  
SNPHarvester and Random Jungle rank SNPs according to a measure of their 
influence allowing for interactions, but these methods do not specifically test the 
interaction effects. Therefore, the top 1000-ranked SNPs from these methods were 
put through 100 iterations of the HyperLasso (Hoggart et al., 2008), along with all of 
their 2-way interactions, in order to select the best terms for the model describing the 
association with the phenotype. I chose to take this number of SNPs and interactions 
mainly for practical purposes, as a reasonable number of terms to take forward to the 
HyperLasso.  To select the Random Jungle SNPs, they were simply ranked by their 
variable importance measures and the top 1000 selected.  For SNPHarvester, SNPs 
were ranked by p-value regardless of whether the p-value was generated in the initial 
single-SNP screening or the pairwise analysis.  This allows for interaction effects in 
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the presence or absence of marginal effects.  Each SNP in a pair was assigned the 
same p-value, so that both SNPs of any pairs would be selected together if they were 
ranked in the top 1000.  
The HyperLasso algorithm is based on a penalised maximum-likelihood approach, 
and the penalty can be considered to be similar to a prior in a Bayesian framework.  
The goal of the HyperLasso is to maximise: 
log𝑝 𝛽 𝑥,𝑦 = 𝐿 𝛽 − 𝑓(𝛽) 
where:  
𝛽 - the set of regression coefficients (e.g. the SNP effects) 𝑥 - the set of genotypes for all individuals over all SNPs 𝑦 - the case/control status of all individuals 𝐿 (𝛽) - the likelihood of 𝛽 𝑓 (𝛽) - a function of 𝛽, applied as a penalty 
I used a Normal-Exponential-Gamma prior and approximated the type-I error rate as 
suggested by Hoggart et al.  The values of 𝛽 are optimised using Newton's method.  
Notably, if a 𝛽 changes sign (e.g. passes 0), it is very unlikely it will be able to move 
from zero, and terms with zero coefficients are removed from the final model.  A 
non-zero coefficient is considered to be a significant term.  
The HyperLasso software limits the genetic data to a count of minor alleles carried 
by an individual at a single SNP; that is, the data must be 0, 1 or 2.  In our interaction 
model I have assumed that genetic effects are additive (on the log scale of the 
logistic regression model) and the interaction term is therefore the product of the 
number of minor alleles carried by an individual at two SNPs.  This could be 0, 1, or 
2 but also 4 in the case of a person who is homozygous for the minor allele at both 
 70 
loci.  I therefore amended the HyperLasso software to accept 4 as a valid data value.  
This allows the interaction data to be used, but the software will not force the main 
effects of an interaction term into the final model.  In order to verify interaction 
terms, I therefore fit a logistic regression model for each interaction term selected by 
the HyperLasso including the main effects, then I dropped the interaction term and 
carried out a 1d.f. likelihood ratio test. 
Over the iterations of the HyperLasso, different SNPs that are in high LD may be left 
in the model to account for the same signal.  Comparing results across iterations may 
therefore miss strong signals because the signal is divided between these SNPs.  To 
avoid this, SNPs were assigned to LD blocks based on an r2 value of 0.5 or greater 
and these blocks were examined for overlap across iterations instead of the 
individual SNPs (Figure 3).  I began at the first SNP on each chromosome and 
progressed along the chromosome, checking LD with the previous SNP.  If the r2 
value was 0.5 or greater the SNP was added to the current group; otherwise a new 
group was created with the new SNP.  Each group was then assigned an identifier in 
the form of chr1block1, meaning the first block on chromosome 1.  Groups can have 
as few as a single SNP and there is no upper limit to the number of SNPs.  These 
new chromosome/block terms were then used to amalgamate results across iterations 





r2=0.8 r2=0.65 r2=0.45 
SNP1 SNP2 SNP3 SNP4 
Block 1 Block 2 
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Figure 3. Assignment of SNPs to blocks 
To account for population stratification in the HyperLasso, the first principal 
component was added to the model as a non-genetic covariate.  This was also 
included in the follow-up logistic regression modelling. 
2.3.4 Sparse Partitioning 
Sparse Partitioning is a Bayesian regression method for identifying groups of 
associated SNPs. The method attempts to find groups of SNPs associated with a 
phenotype and define the best 'partition' of the predictors.  For example a group of 
three predictors which are associated with a response could consist of three 
independent main effects, one pairwise interaction with a main effect, a three-way 
interaction, or, if using a SNP in multiple partitions is permitted, two interaction 
effects (e.g. SNP1 * SNP2 and SNP2 * SNP3). The user provides a prior parameter 
defining how many associated predictors there are likely to be in total, the possible 
depth of interactions (such as 2 for pairwise interactions only or 3 for 2-way and 3-
way interactions) and if SNPs can be used in multiple partitions. The solution is 
assumed to be sparse, meaning only a few predictors are likely to be causal.  Larger 
priors for the total number of SNPs and interaction depth will considerably slow 
down the computation of the solution. 
The original Sparse Partitioning algorithm is a stochastic search, meaning that it 
randomly searches through the space of all possible partitions, moving predictors 
into and out of groups at each iteration; at the end it calculates posterior probabilities 
of association and pairwise probabilities of interactions by recording how often each 
predictor was in a non-null group and how often two predictors were in the same 
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non-null group. This solution does not scale up for whole-genome data; the 
computational burden is too great.  Instead I used the modified deterministic version 
(Speed, 2010) which is somewhat similar to stepwise regression.  For each of a 
sequence of moves, a SNP is either added, removed or swapped to the group of 
predictors associated, and the process stops when the score cannot be improved. This  
method allows the user to specify an exact number of associations.  If the best 
solution does not contain this number of SNPs the process will restart, either adding 
or removing predictors until it selects the specified number.  
For this study Sparse Partitioning was set to choose four predictors, and up to two of 
those could be two-way interactions, hence a total of 4 to 6 SNPs would be in the 
final group of associated SNPs.  The number of predictors in the final model is 
chosen mainly for practical reasons, as larger models dramatically increase 
computational time. 
The first principal component, as used by Strange et al, was given a prior probability 
of 1 to force it into the model.  The top SNP in the MHC region was also given a 
prior of 1, as the effect is very large and not in doubt.  Sparse Partitioning was 
sensitive to genotyping errors and was initially selecting only SNPs that proved to be 
badly called in either the cases or the controls, creating large differences in allele 
frequencies between them.  To avoid this problem I set a more stringent threshold for 
Hardy-Weinberg equilibrium (p<0.004) and applied it to cases and controls, which 
removed the problem SNPs.   
2.3.5 Replication 
I attempted replication of all SNPs involved in pairs that were selected by all 100 
iterations of the HyperLasso on the SNPHarvester results.  When more than one SNP 
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pair contributed to an LD block I attempted to replicate every pair.  Data from the 
Collaborative Association Study of Psoriasis (CASP) study was used for replication 
(Nair et al., 2009).  This study genotyped samples on a Perlegen platform (see Nair et 
al. for details).  SNPs for replication of the SNPHarvester interactions which were 
not genotyped were imputed with IMPUTE2 software (Howie et al., 2009), using 
data from the July 2011 release of the data from the1000 Genomes Project (1000 
Genomes Project Consortium, 2010b).  
I also attempted replication of a novel single-SNP association selected by Sparse 
Partitioning. This SNP had a perfect proxy SNP (r2=1) in the CASP study and this 
was used for replication. 
For replication of interactions, a logistic regression model was fit to the imputed 
CASP data with the interaction terms of interest and their main effects. I then fit a 
second model without the interaction term and carried out a 1 d.f. likelihood ratio test 
to test if the interaction term accounts for any extra variance beyond that explained 
by the main effects. The Bonferroni corrected level of significance required 
accounted for all of the terms in all of the models in the replication stage. A logistic 
regression model was also fit using the proxy SNP from the CASP data to replicate 
the novel SNP found by Sparse Partitioning. To test the significance of the SNP I 
dropped it from the model and carried out a likelihood ratio test. 
2.4 Results 
2.4.1 SNPHarvester 
SNPHarvester results can be divided into single-SNP associations removed before 
pairwise analysis and pairs selected for their combined association with psoriasis 
case/control status.  Seven hundred and ninety-five SNPs were removed in the first 
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stage with strong single-SNP p-values, and 3593 SNP pairs were selected by 
SNPHarvester.  In total from both single-SNPs and pairs there were a total of 1549 
unique SNPs selected by SNPHarvester. Table 3 gives the p-values for SNPs that 
were discovered or replicated in the WTCCC study alongside the SNPHarvester 
rankings.  A large proportion of the SNPs selected by SNPHarvester were in the 
MHC region, so the SNP rankings are given including all SNPs in the MHC region 
and without them.  Since this study uses the data from the WTCCC study, it is 
reasonable to expect that SNPHarvester should rank the SNPs from their results 




Table 3. SNP hits (p<10-7) from WTCCC study with rankings from SNPHarvester and Random 
Jungle.  
The symbol "-" indicates that this SNP was not selected or ranked. 




rs10484554 6 31382534 4.06E-214 38 (36) 14 (14) 
rs240993 6 111780407 5.29E-20 184 (139) 1745 (291) 
rs458017 6 111802784 2.16E-16 249 (203) 1702 (279) 
rs17716942 2 162968937 1.06E-13 797 (733) 1801 (301) 
rs8016947 14 34902417 1.52E-11 - 1632 (266) 
rs27524 5 96127700 2.56E-11 - 1651 (271) 
rs3213094 5 158683347 4.93E-11 - 1759 (298) 
rs4112788 1 150817900 3.32E-10 121 (82) 1712 (282) 
rs702873 2 60935046 3.59E-09 - 1884 (319) 
rs6809854 3 18759427 1.12E-07 1906 (1813) - 
*4 SNP hits are not listed here because they were not replicated by SH or RJ. 
2.4.2 Random Jungle 
Random Jungle results consist of variable importance measures for all SNPs.  There 
is no particular VIM value for a measure of statistical significance, but SNPs can be 
ranked by these VIMs. 
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Table 3 includes the Random Jungle VIM rankings for the SNPs previously 
association with psoriasis.  I used the top 1000 SNPs here as I did for the 
SNPHarvester results, and these SNPs and their interactions were taken forward to 
the HyperLasso.  There are several SNPs in the table which do not have rankings 
from Random Jungle - these SNPs were given a VIM of zero or very close to zero, 
indicating that the genotype data including this SNP classified individuals with the 
same accuracy as the permuted SNP data.  In effect this means that Random Jungle 
did not identify these SNPs as important in distinguishing cases and controls in 
psoriasis. 
 
Figure 4. Workflow for SNPHarvester and Random Jungle Analyses 
2.4.3 HyperLasso 
The workflow and a summary of results for both the SNPHarvester and Random 
Jungle analyses is shown in Figure 4.  Each of the 100 iterations of the HyperLasso 
applied to the SNPHarvester top 1000 SNPs left between 185-217 terms in the model 
with non-zero coefficients.  After converting the SNP pairs to blocks (see section 
2.3.3) many SNPs appeared in multiple iterations but only 14 terms were present in 
all 100 iterations.  These were all interaction terms.  After the Random Jungle top 
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1000 SNPS and their interactions were put through the HyperLasso there were 
between 323 - 360 terms with non-zero coefficients, with 13 present in all 100 
iterations.  Again these were all interaction terms.  There was no overlap between 
these SNPHarvester and Random Jungle pairs.  Table 4 shows the number of terms 
that were present in various numbers of iterations of the HyperLasso for 
SNPHarvester and Random Jungle results.  There is no overlap between any of the 
terms from SNPHarvester and Random Jungle in this table.  For example, there are 
105 terms from the Random Jungle results that were selected by at least 80 iterations 
of the HyperLasso. Likewise there were 61 such terms from SNPHarvester that were 
selected by at least 80 iterations of the HyperLasso.  However there were no terms 
that were selected by at least 80 iterations of the HyperLasso on both sets of results.  
In total there were 38 terms which had non-zero coefficients in at least one iteration 
of the HyperLasso from both the SNPHarvester and Random Jungle results, but these 
terms were found in far more iterations from one method than the other, and there are 
no obvious choices of terms that were found in many iterations from both. 
Table 4. Number of terms from SNPHarvester and Random Jungle that were selected in a large 
number of iterations of the HyperLasso 
Iteration count cut-off Random Jungle terms SNPHarvester terms 
100 13 14 
>90 66 38 
>80 105 61 
 
Our positive control - the interaction between SNPs in HLA-C and ERAP1 - was not 
discovered by the Random Jungle arm of the study.  The VIM for the ERAP1 SNP 
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involved in this interaction was not ranked among the top 1000 VIMs, so the 
interaction between this SNP and the HLA-C SNP was not a term in the HyperLasso 
model.  SNPHarvester did rank the ERAP1 SNP as one of the top 1000, and the 
HyperLasso gave the interaction term between ERAP1 and HLA-C a non-zero 
coefficient in 77 of 100 iterations.   
2.4.4 Sparse Partitioning 
To limit computational time, I required that the model selected by Sparse 
Partitioning should contain 4 SNPs. There are 10 possible partitionings of four 
predictors (allowing at most two pairwise interactions). Sparse Partitioning 
determined that the model with all predictors in separate groups (i.e. with no 
interactions) was most likely in light of the data and the prior settings (posterior 
probability 0.74). This model explained 46% of the variance on the observed scale. 
The p-values for these SNPs from the single-snp association study are given in  
Table 5. 
Table 5. Single-SNP p-values (log-additive genetic model) for SNPs selected by Sparse 
Partitioning model 
Chromosome Position SNP Single-SNP p-value 
6 31382534 *rs10484554 2.2 x 10-216 
6 31557973 rs2516509 5.265e-77  
6 30048729 rs2256919 4.134e-30 
5 158791476 rs10059288 1.688e-18 
6 111687254 rs11153277 1.69e-10 
*This SNP was given a prior probability of 1 and is not included in the 4 SNPs chosen by SP 
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SNP rs2516509 is in moderate LD (r2=0.18) with the strongly associated classical 
HLA allele HLAC*0602 but is not in LD with the top SNP (rs10484554).  This SNP 
has recently been discovered as an independent signal in the MHC region which 
persists after conditioning on the top known MHC region hits (Knight et al., 2012).  
SNP rs2256919 is in almost perfect LD (r2=0.98) with another independent MHC 
signal at SNP rs380924, also discovered by Knight et al.  SNP rs10059288 was a 
previously unpublished association approximately 1kb from the gene IL12B.  This 
SNP is not on the Perlegen platform, but rs10515802 is a perfect proxy (r2=1.0 in 
CEU population of the Thousand Genomes project). This SNP had a p-value of 4.6 x 
10-7 from the likelihood ratio test using the CASP study data.  Since the analysis this 
SNP has been published in an analysis of psoriasis using the immunochip platform 
(Tsoi et al., 2012).  The last association detected by Sparse Partitioning, rs11153277, 
is also on chromosome 6 and is in high LD (r2=0.81) with SNP rs240993, reported by 
Strange et al (p=8.7 x 10-13).  
2.4.5 Replication of Interactions from SNPHarvester Results 
SNPHarvester was the only method that selected the known interaction in psoriasis 
which acted as our positive control.  It therefore seemed the most likely method to be 
finding real interaction signals. I chose to follow up on promising results from this 
arm of the study to try to find novel interactions in psoriasis.  I identified the blocks 
that were present in all 100 iterations of the HyperLasso and found the SNP pairs 
within these blocks. Logistic regression interaction p-values from the WTCCC2 and 
CASP studies are given in Table 6, along with the info score from the imputation of 
the SNPs from the CASP study. None of the putative interaction signals suggested by 
SNPHarvester were significantly associated with psoriasis in the replication dataset.  
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Table 6. Replication of SNPHarvester interacting SNP pairs 
P-values from the WTCCC2 and CASP likelihood ratio tests of interactions.  Sequential rows 
with the same shading indicate SNP pairs from the same block pairs. 








































1p31.3 6p22.1 9.29*10-5 0.847 0.512 
0.825 
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6p22.1 6p21.3 6.8*10-4 0.170 0.957 
0.690 
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The level of overlap between SNPHarvester and Random Jungle was not high 
enough to confidently identify promising interaction signals.  If the two different 
methods had found the same interaction in most of the HyperLasso iterations, this 
would have provided more convincing evidence in support of these methods and the 
interactions they have found, particularly if any of the new interactions had 
replicated in our independent data.  However this was not the case, and it was not 
possible to identify promising pairs of SNPs based on the degree of overlap between 
their results. 
The SNPs in our positive control interaction (HLA-C * ERAP1) were found by 
SNPHarvester, and their interaction term had a non-zero coefficient in 77 of 100 
iterations of the HyperLasso.  This is encouraging and it seems that, for this data set, 
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SNPHarvester was the only method able to detect the true interaction signal in this 
data.  
For this reason I decided to follow up the SNPs that were selected in all 100 
iterations of the HyperLasso on the SNPHarvester results.  However, attempts to 
replicate these signals in the CASP study data were unsuccessful.  The SNPHarvester 
results could simply be false positives which will not replicate in any other data set, 
but the imputation quality of many of the SNPs was very poor. This would result in a 
loss of power to detect association signals.  The CASP study was smaller than the 
WTCCC study, again reducing the power to detect association signals.  In the 
absence of further, better quality genome-wide data for replication it not possible to 
confirm the interactions found by SNPHarvester, but it is also impossible to be 
certain they are not real. 
Sparse partitioning identified main effects from 4 SNPs in addition to the top SNP 
from the GWAS, which was included as a covariate.  Two of the further SNPs were 
shown by Knight et al to be independent associations within the MHC region.  My 
findings indicate that Sparse Partitioning is able to identify independent signals in the 
same region that may be missed if study analysts simply select the top SNP in a 
region for follow-up.  A further SNP on chromosome 6 has been previously reported 
as associated with psoriasis.  Interestingly, Sparse Partitioning found a SNP on 
chromosome 5 which is not in LD with any SNP previously identified as associated 
with psoriasis, and the finding was replicated in the CASP data.  This SNP is very 
near to another SNP that was identified in the WTCCC study, and it is likely that the 
analysts chose the top SNP in the region for follow-up.  The SNP was confirmed and 
has now been published in another study. Although Sparse Partitioning did not 
identify any interactions, the SNPs it did select are sensible choices, and this method 
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has proven to be particularly good at identifying independent signals which may 
otherwise be overlooked due to proximity to other associations.   
Although the methods in this study did not all replicate the findings from the original 
study, this is not surprising due to the different search strategies used.  The 
interaction was originally discovered by specifically modelling interactions between 
all pairs of SNPs that showed single-SNP associations. This resulted in 153 tests, so 
an appropriate significance threshold is 0.05/153 = 3.3x10-4.  The interaction p-value 
was 2.45x10-5 which, while significant in this context, would not be an unexpected 
finding due to chance in a genome-wide interaction analysis with many more tests 
being carried out.  
The multiple testing burden explains why the methods in this study were generally 
not as successful at finding this interaction, but does not explain why SNPHarvester 
was successful and Sparse Partitioning and Random Jungle were not.  Sparse 
Partitioning is a processor-intensive method which requires much more computing 
time when more predictors are allowed to come into the model.  There are many 
SNPs which are strongly associated with psoriasis.  The study from which this data 
was taken listed 18 independent SNPs which were either newly-discovered or 
replicated in this data.  All of these SNPs have a larger effect size than the interaction 
I was hoping to discover.  Given that I had to limit Sparse Partitioning to selecting no 
more than 4 predictors it quite naturally selected those with stronger effects, which 
were all single-SNP associations.  Random Jungle relies on the random selection of 
of SNPs available at each node in each tree.  To influence the tree, one interacting 
SNP would have to be available at a node and be selected as the split variable over 
all others at that node. Then the second interacting SNP would have to be available 
in the daughter nodes, to allow this split to be dependent on the first SNP.   All of 
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these less-than-certain events mean that the effect of the interaction may not have 
been tested frequently, and if it was it may not have been strong enough to overcome 
single-SNP effects or random noise in the data.  SNPHarvester, unlike the other two 
methods, targets groups of SNPs of a specified size and tests them.  Although there is 
a random element in terms of the starting pair of SNPs, once these are selected the 
algorithm then cycles through and considers all SNPs in the genome.  There is a 
reasonable chance that SNPs which truly interact will be tested together for 
association, and this will increase their variable importance measure.  This may give 
SNPHarvester an advantage in finding interactions in GWAS data.  
The results of this study highlight the difficulties involved in finding statistical 
interactions in GWAS data. If additional genetic interaction effects exist for 
psoriasis, then their effect sizes must be small.  Given these difficulties, I believe it is 
best to use multiple methods to try to find interaction effects in GWAS data, as there 
may be no single best method. Checking for interactions between top single-snp 
associations is a sensible starting point.  Of the three methods compared here, 
SNPHarvester was the only one that had reasonable success in finding the known 
interaction, and therefore might be a good choice to start the search for interactions 
in a GWAS data set.  
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3 Searching for Evidence of Genetic Interactions in 
Protein-Protein Interactions 
The search for genetic interactions in genome-wide association studies has met with 
limited success to date.  Although significant interactions have been found in several 
studies using a variety of methods, they have rarely been replicated in independent 
data sets. The question of how frequent these hypothesized interactions actually are 
has still not been answered, although if they were common with large effect sizes 
then it is likely that more would have been found.  It is possible, however, that there 
are many of these interactions that have not yet been found, but they have small 
effect sizes and are thus difficult to find with available statistical methods and 
sample sizes.  
Finding a statistical association is simply a tool for discovering some sort of 
biological association that affects a particular phenotype.  The belief is then that 
understanding the biology will help with the understanding of the phenotype.  For 
example if the phenotype is a disease, then the genetic associations, whether they are 
due to a single SNP or a combination of SNPs, may highlight a biological pathway 
that could be a target for a treatment.  In the case of multiple SNPs, a statistical 
interaction may be evidence that the end products created from the genetic 
sequences, the proteins, are interacting to affect the phenotype.  While there is not 
very much evidence of strong statistical interactions in genome-wide association 
studies, there is quite a bit of publically available information on proteins that have 
been shown experimentally to interact with each other.  
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One could search for statistical interactions using biological information (e.g. 
pathway analysis, protein-protein interaction networks, co-expression data) to narrow 
the search space to genes where there is an a priori reason for believing there may be 
a biological interaction.  In this study, rather than targeting areas to search for a 
strong association signal from specific pairs of SNPs, the focus is on looking for a 
general enrichment of a statistical signal from SNP-pairs within gene-pairs that code 
for proteins involved in known biological interactions (Protein-Protein Interactions, 
or PPIs).  If there is a tendency for statistical interactions to occur in these pairs, then 
it is sensible to hypothesize that statistical interactions do indeed occur when 
biological interactions are present, and the search for these interactions is a sensible 
way forward.  If there is little evidence for a general trend for statistical interactions 
to occur alongside biological interactions, then perhaps the search for these 
interactions is not a sensible direction to take.  Instead resources could be directed to 
increasing sample sizes in single-locus studies, or using sequencing technology to 
find rare variants.  
I have created a software tool which starts with a list of PPIs, a map of SNPs to 
genes coding for these proteins and GWAS data.  The output from this program 
enables the computation of a pair of test statistics which summarize the p-values 
from SNPs in genes coding for interacting proteins, along with a null distribution 
created by permuting the input data. 
3.1 Statistical Methods 
The analysis is carried out in several stages.  First, all pair-wise interaction p-values 
are calculated for all input SNPs.  This includes the pairs of SNPs from the paired 
genes, but also all other combinations of SNP pairs.  Calculating the p-values from 
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SNP pairs which are not interacting will allow the creation of a null distribution for 
our test statistic.  Next, two test statistics are calculated by summarizing selected p-
values from SNPs within the genes in the paired gene list.  Finally, a permutation 
scheme runs a user-defined number of permutations which allows the creation of null 
distributions for both test statistics.  Each of these stages is described in detail in the 
following sections, and the outline algorithm is given in Figure 6. 
3.1.1 Interaction p-values 
After creating our list of SNPs for analysis we calculated a p-value for interactions 
using PLINK's fast-epistasis command.  This carries out a test for differences in odds 
ratios between cases and controls.  The interaction coefficient β in a logistic 
regression model is the same as the ratio of the odds ratios of the cases and controls. 
Equation 8. Interaction coefficient in logistic regression β   =   log(R/S)   =   log(R)   −   log(S) 
If the two odds ratios are the same, then R/S=1and β=log(1)=0, indicating that there 
is no interaction between the two loci.  PLINK's implementation of this test is given 
in Equation 9. 
Equation 9. Plink's fast-epistasis test Z   =    (  log(R)   −   log(S)  )    /  sqrt(  SE(R)   +   SE(S)  ) 
where R is the odds ratio of the two alleles in cases and S is the odds ratio of the two 
alleles in controls.  This follows a standard normal distribution.  
PLINK's fast-epistasis command is not quite equivalent to the test of the logistic 
regression coefficient since the phasing of the alleles between the two loci is not 
known, as it would be in the equivalent logistic regression model.  PLINK's odds 
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ratios are calculated simply with allele counts.  However the authors claim that the 
correlation between PLINK's test and logistic regression is very high (r=0.995). 
3.1.2 Test Statistics 
The purpose of the test statistic in this study is to summarise the interaction p-values 
for SNP pairs from gene pairs involved in PPIs and compare them to p-values from 
SNP pairs that aren't involved in PPIs.  I have implemented the calculation of two 
test statistics that might be useful for this comparison, one based on a summation and 
the other a proportion. 
The first test statistic involves summing a transformation of the p-values across all 
SNPs within genes coding for known interacting proteins (see Equation 10).   
Equation 10. PERSI test statistic: sum of interaction p-values 
𝑇! = (−2 ∗ ln 𝑝! )!!"#!!!  
where: 
nint is the number of SNP-pair p-values from interacting gene pairs 
pi is the p-value for the interaction from the ith interacting SNP pair. 
An alternative to simply summing p-values, this transformation makes the meaning 
of the sum more intuitive, so that the higher the value of the test statistic, the more 
significant the results. The total sum is then adjusted by dividing by the number of 
values summed, as this can vary depending on the number of SNPs in the genes that 
are included.  It can be shown (Fisher, 1925) that T1 follows a chi-square distribution 
with 2*nint degrees of freedom under the null if all p-values were obtained from 
independent tests. Thus E[T1/nint]=2 regardless of the number of SNPs. In our case, 
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the p-values are unlikely to be independent but it is still reasonable to suppose that 
E[T1/nint] is a constant. 
Although we are searching for an enrichment of low p-values, it is not expected that 
the number of interacting pairs will be a large proportion of the total that are 
considered.  Because of this there is a large amount of 'noise' in the data, because the 
likelihood of any one SNP pair being important is low. In order to reduce this noise, 
we applied this same summation to only SNP pairs whose p-values met certain user-
defined thresholds.  
Equation 11. PERSI test statistic: sum of transformed p-values below user-defined threshold 
𝑇! = (−2 ∗ ln 𝑝! )!!"#(!!)!!!  
where: 
nint(p1) is the number of SNP-pair p-values from interacting gene pairs that are below 
threshold p1 
If there is an enrichment of low p-values within our target SNP pairs, then the test 
statistic based on the sum of the transformed p-values will be higher than that 
obtained by summing p-values from other SNP pairs. 
The second test statistic was the proportion of 'significant' p-values between PPI 
SNPs, again at various user-defined thresholds.  If statistical interactions can be 
found from SNP-pairs within genes coding for protein-protein interactions then a 




Equation 12. PERSI test statistic: proportion of low p-values between SNPs in PPIs 𝑇! =   𝑛!"#(!!)𝑛!"#  
As with T1, this value should be higher if there are more interacting SNP pairs from 
the gene pairs in the PPI list than from other pairs of SNPs.  This proportion is then 
compared to the null distribution generated from the permutation stage. 
3.1.3 Permutation scheme 
To assess the importance of the test statistics we devised a permutation scheme to 
create a null distribution and compared our test statistic to this to calculate an 
empirical p-value.  In order to preserve the genetic structure of the data (for example, 
variable gene sizes and linkage disequilibrium) we permuted only the gene labels 
within the gene-pair list and recalculated our two statistics in a manner similar to a 
Mantel test (Mantel, 1967) (see Figure 5).   
 
Figure 5. Permutations scheme for gene labels 
Green highlighting indicates the interacting gene pairs (1 & 3, 2 & 4) used to calculate the test 
statistic.  The real gene labels are given in a), while in b) the gene labels are permuted but the 
SNP labels stay the same, preserving gene structure.  The green areas in a) will contribute to 
the real test statistic, while the green areas in b) will contribute to a value from the null 
distribution. 
The list of SNPs belonging to a single gene remained the same, but the identifier of 
the gene changed.  The list of interacting gene pairs also remained the same. As a 
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reminder, for both statistics a higher than expected value for the real test statistic will 
indicate an enrichment of low p-values in the SNPs involved in PPIs. 
The algorithm for the whole process is given in Figure 6.  
Inputs:  
D: genotype data for Na cases and Nu controls 
PVALS: a set of M p-value thresholds 
PPI: a paired gene list 
S2G: a SNP-to-gene map 
NPERM: number of permutations 
RESULTS: name for results file 
Output:  
1. Simplified interaction p-values file for further analyses 
2. Results file with counts and summed -2*ln(p) for each threshold for real data 
(first row) and permuted data (next NPERMS rows) 
Create set list SNPSET of all unique SNPs in S2G 
Create gene list GENELIST from all unique genes in S2G 
Call PLINK to calculate interaction p-values from D, between all SNPs in SNPSET 
and output results to file SNPINTS 
#Simplify each result to an integer-format gene-pair ID and associated p-value 
Read in SNPINTS, S2G, GENELIST 
For i in 1:length(SNPINTS) 
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Replace pair of SNP identifiers with gene pair identifier: 
Look up corresponding genes for both SNPs in S2G 
Get position indices for these genes from GENELIST 
Combine GENELIST indices using the formula (m+1)*NGENES + 
(n+1), where m is the smaller index and n is the larger 
Resulting integer is a unique PAIRID for this gene pair 
Output PAIRID and current p-value to the file GENEINTS_SIMPLIFIED 
 
#Calculate test statistics for each p-value threshold, carry out permutations 
Read in GENEINTS_SIMPLIFIED, PPI, PVALS 
For i in 1:(NPERM + 1) 
Count total number of p-values for PAIRIDs corresponding to gene pairs in 
PPI and store in PCOUNT.ALL 
Sum -2*ln(p) for all p-values for PAIRIDs corresponding to gene pairs in PPI 
and store in PSUM.ALL 
Output to RESULTS (line i) as space-delimited: PAIRID PCOUNT.ALL 
PSUM.ALL 
For j in 1: length(PVALS) 
Count p-values below PVAL(j), store in PCOUNT.j 
Sum -2*ln(p) below PVAL(j) and store in PSUM.j 
Output to RESULTS (line i) as space-delimited: PCOUNT.j, PSUM.j  
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Permute PAIRIDs, retaining gene structure 
Figure 6. PERSI algorithm.   
The process is managed by a bash shell script. It calls PLINK to calculate interaction p-values, 
and two C++ programs to 1) simplify PLINK results and 2) calculate statistics and permute data.  
The simplification step can be skipped if the simplified results file is already available from a 
previous analysis. 
3.2 Application to WTCCC Crohn's data 
The Wellcome Trust Case Control Consortium (WTCCC) carried out a genome-wide 
association study in Crohn's disease (Wellcome Trust Case Control Consortium, 
2007), and this data is freely available to researchers. Genotyping was done on the 
Affymetrix GeneChip Mapping 500k assay.   
3.2.1 Quality Control 
Data from the WTCCC study is available separately for each of 7 phenotypes and 2 
sets of unscreened population controls.  For this study I used the Crohn's disease 
cases (CD), National Blood Service (NBS) and 1958 birth cohort (58BC) controls, 
all of which were genotyped at 500568 SNPs. There were 2009 CD, 1500 NBS and 
1504 58BC individuals genotyped.  Each of the three data sets came with a list of 
SNPs and individuals that failed quality control (QC) carried out by the WTCCC.  
As an extra check I merged the three files together first and then carried out QC 
procedures, to ensure that the merged data set was as clean and high-quality as 
possible.  I used the same thresholds used by the WTCCC in their QC (see Table 7), 
and I removed individuals before carrying out SNP level QC.  Due to the two control 
sets being genotyped separately it was sensible to check for significant differences in 
allele frequencies between them.  I carried out a pseudo-association study using 
NBS/58BC status as case/control status, and excluded SNPs on the basis of highly 
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significant p-values.  Summaries of the individuals (Table 8) and SNPs (Table 9) 
removed by my QC and the WTCCC QC are given below. 
After carrying out my QC as described I then ensured that all SNPs and individuals 
in the WTCCC exclusion lists were removed.  As a result, all SNPs or individuals 
who were problematic in either the separate data files or the combined data set were 
removed from the analysis.  
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Table 7. Quality control thresholds for merged WTCCC Crohn's data and controls 
QC metric Threshold 
Individual Missingness 3% 
 Sex check Phenotype/genetic mismatch or 
0.2<F<0.8 
 Heterozygosity <0.225 or >0.3  
SNP Missingness (Miss) and 
Minor Allele Frequency 
(MAF) 
Miss>0.05 OR 
Miss>0.01 AND MAF < 0.05 
 HWE 5.7*10-7 
 Trend (NBS vs 58BC) 5.7*10-7 
 X-chromosome All  
 
Table 8. Individuals removed by author's QC, WTCCC QC and combined.  
  Number removed 






Missingness > 3% NBS 8 8 8 
58BC 9 9 9 
CD 44 48 48 
All miss 61 65 65 
 97 
     
Sexcheck  NBS 0 2 3 
58BC 0 3 2 
CD 0 1 1 
All sex 0 6 *6 
     
Heterozygosity NBS 0 0 0 
58BC 0 0 0 
CD 4 4 4 
All het 4 4 **4 
     
***Other reasons NBS 34 0 34 
58BC 15 0 15 
CD 209 0 209 
All others 258 0 258 
     
Grand totals NBS 42 10 45 
58BC 24 12 26 
CD 257 53 262 
All cohorts 323 75 333 
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*Author's sex check found 15 individuals – 9 of these were included in the WTCCC removals 
for ‘other reasons’, and are not included here. 
**Author's heterozygosity check found 9 individuals – 5 were included in the WTCCC removals 
for ‘other reasons’ and are not included here.  
***Other reasons for exclusion by WTCCC- Affy CEL file bad, external discordance (DIL 
genotyping, NBS blood type, phenotype measure in CD), non-European ancestry, sent twice by 
Sanger, duplicated at unknown stage, 1st/2nd degree relatives 
 
Table 9. SNPs removed by author's QC (after merging 3 files) and WTCCC QC (performed 
separately on each file). 
Reason Author's QC WTCCC 
Missing/MAF 24910 26190 
HWE 4381 4303 
Trend 103 93 
X-chr 10152 370 
Total 39456 30956 
 
After quality control measures were applied, there were 458210 SNPs genotyped in 
1747 Crohn's disease cases and 2933 controls.  
 
3.2.2 Protein-protein interactions and SNP-gene mapping 
Protein-protein interactions were identified by a bioinformatician colleague 
Benjamin Lehne, using information from 5 manually curated databases according to 
his previously described work (Lehne and Schlitt, 2009).  In order to be as certain as 
possible that we were including only true PPIs, only those that had been confirmed in 
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at least two independent publications were used.  All interactions that arose from 
well-known protein complexes as defined by MIPS CORUM (downloaded 
3.06.2008) were removed.  All genes that had an interaction in the above set were 
mapped to the WTCCC Crohn's disease study SNPs.  For mapping SNPs to genes, a 
SNP had to lie within a gene or 5kb to either side of the gene. SNPs that could not be 
assigned unambiguously (for example, they were within mapping distance to more 
than one gene) were removed.  
The above exercise resulted in 
• 1015 protein-protein interactions 
• 1165 genes coding for these proteins 
• 15010 SNPs from Affy 500 mapped to these proteins 
• 112,642,545 possible SNP pairs 
• 86,231,572 pairs after excluding SNPs for QC.  
Our first test statistic, the sum of the transformed p-values, was calculated for all 
SNPs in the PPIs as well as including only p-values below the thresholds 0.10, 0.05, 
0.01 and 0.005.  Our second test statistic, the proportion of p-values below a 
threshold, was calculated at p-value thresholds 0.05, 0.01 and 0.005.  
3.2.3 Results 
The first stage of PERSI produces p-values for all pairwise comparisons of SNPs 
given to PLINK in the SNP set list.  This represents a set of SNPs in which there is 
some reason to believe there may be biological interactions. It is therefore sensible to 
check the individual p-values for these SNP pairs.  The most significant p-values 
from the PLINK fast-epistasis analysis are given in Table 10. Given that we are 
testing 86 231 572 SNP pairs, a reasonable Bonferroni-corrected level of significance 
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is 0.05/86231572 =5.8*10-10.  There are no SNP pairs with a p-value lower than this, 
so we have not found any interacting SNP pairs that are significantly associated with 
Crohn's disease. 
Table 11 contains the results from the analysis using all of the p-value thresholds we 
applied. There is no evidence here to support our hypothesis that there is an 
enrichment of low p-values within genes coding for proteins involved in protein-
protein interactions.   
Table 10. Top interaction p-values for PLINK's fast-epistasis analysis on SNPs in genes coding 
for proteins involved in protein-protein interactions 
SNP1 SNP2 p-value 
rs10276324 rs17570793 1.84E-08 
rs11208830 rs12108497 3.17E-08 
rs3845731 rs17536147 5.26E-08 
rs17507748 rs2919387 7.26E-08 
rs17507685 rs2919387 9.60E-08 
rs2918417 rs12934281 9.74E-08 
rs1934909 rs500629 1.08E-07 
rs7894595 rs8114927 1.31E-07 
rs2918417 rs7196708 1.54E-07 
rs2918417 rs11647877 1.71E-07 
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Table 11. Empirical p-values for two test statistics at multiple p-value thresholds. 
 Empirical p-value  
p-value threshold  ∑-2ln(p)   proportion 
all results 0.77 - 
p<.05 0.08 0.28 
p<.01 0.10 0.12 
p<.005 0.23 0.13 
 
3.3 Discussion 
None of our tests have provided convincing evidence of an enrichment of low p-
values in SNP pairs corresponding PPIs in Crohn's disease.  There are hints of 
enrichment at some thresholds, but it is difficult to hypothesize as to why these 
particular thresholds should be important, and we certainly can't rule out that these 
modestly low p-values are due to chance. 
One limitation of this study is the application in just one phenotype.  There is no 
particular reason to believe that PPIs are important in Crohn's.  It was selected for 
convenience, as one of many phenotypes for which there is now publically available 
GWAS data.  
The genotyping in the WTCCC Crohn's study was done on the Affy500k chip, but 
more modern chips offer better coverage of the genome.  Denser, better-designed 
chips may be more successful in tagging or typing causal variants, which will 
increase the probability of finding both single-SNP effects and interactions, since the 
power to detect statistical effects will decrease with imperfect tagging.  
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PERSI is designed to look for an enrichment of low p-values within gene pairs, but 
this will not necessarily be present if a phenotype is strongly influenced by a single 
SNP pair, or a single pair of genes.  In this case the statistical noise from all of the 
pairs that are not associated with the phenotype, but are in our list of reported 
interacting pairs, could mask the signal from the true interacting SNPs.  In this case 
other methods for detecting SNP-SNP interactions would be more useful.  
Examining the interaction p-values from all of the SNP pairs is an obvious starting 
point, but in this particular study there were no particularly low p-values.   
Our processes of selecting PPIs and assigning SNPs to genes could be further areas 
where a different approach could provide different results.  Any list of gene pairs 
could be used as an input to PERSI, and we have only used one approach of using 
well-published PPIs.  It is also possible to limit the analysis to gene pairs within 
pathways that have been implicated in a particular phenotype, potentially reducing 
statistical noise from the amount of testing done with SNPs that are unlikely to be 
involved. The assignment of SNPs to genes could also be done using different 
methods, for example larger or smaller flanking regions around a gene.   
Investigation of further phenotypes using different GWAS data, gene pair lists and 
SNP-to-gene assignment methods may yet provide evidence of an enrichment of 
interaction signals.   
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4 Genome-Wide Association Study in Renal 
Transplantation 
In this chapter I will describe my contribution to a GWAS in renal transplantation 
that was carried out at King's College London.  
4.1 Background 
The aim of this project was to find genetic variants associated with the survival time 
of a transplanted kidney, as well as a number of secondary phenotypes.  The design 
of this study is somewhat different to a standard GWAS as the unit of analysis for the 
primary phenotype is a transplant, not an individual.  Genotypes from two 
individuals contribute to each transplant event, and it is plausible that genetic 
variants in donors and recipients could both affect the prognosis for the transplant.  
My contribution to this study involved work on a section of the quality control (QC) 
procedures as well as the analysis of the binary phenotypes. I carried out a principal 
components analysis to identify non-Caucasian samples as part of the QC.  I then 
carried out the analysis of three binary phenotypes; progression to end-stage renal 
failure, acute regression and intra-cranial haemorrhage.  I worked on the analysis of 
the main study data collected at King's College London (KCL) as well as a 
replication cohort to follow up the most likely SNPs from each phenotype.  
4.2 Genetic Data and Phenotypes  
Genotyping was carried out in-house at KCL on Illumina Quad 610 chips.  Donors 
and recipients for 625 transplants (1250 samples) were genotyped. One thousand one 
hundred and fifty-two samples (576 complete transplants) passed QC. 
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The primary phenotype for this analysis is time to graft failure in days, however in 
this study I analysed three binary phenotypes in a standard case/control GWAS 
design.  Details of the survival analysis and results that I carried out on an expanded 
data set are presented in Chapter 5. 
4.2.1 End-Stage Renal Failure 
All of the recipients of a kidney transplant have progressed to end-stage renal failure 
(ESRF).  Although the underlying disease may be different, all of these patients' 
kidneys have failed, while other patients with the same diseases will not progress to 
ESRF.  The hypothesis behind this analysis is that there may be an underlying 
genetic cause for progression to ESRF, which could be due to a donor or recipient 
variant or an interaction between the two.  I therefore used all 576 recipients of 
kidney transplants as cases in this case/control analysis.  Various sets of controls 
were used, described below. 
4.2.2 Acute Rejection 
An acute rejection is often defined by sharply raised creatinine levels in blood, but 
for a definitive diagnosis a biopsy is examined for histological changes.  For this 
study only biopsy-confirmed acute rejection episodes were used as cases, and all 
kidney transplant recipients who had 0 recorded AR episodes were used as controls.  
Using this information, there were 173 cases and 356 controls for the case/control 
analysis of acute rejection.  
4.2.3 Intracranial Haemorrhage 
A large proportion of transplant donors in the UK are otherwise healthy victims of a 
sudden stroke.  Donor records indicate the cause of death for deceased donors, and a 
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large number of organ donors have a cause of death of intracranial haemorrhage 
(ICH). This information allowed us to carry out a GWAS in ICH using the donor 
samples that have already genotyped.  
4.2.4 Control Samples 
For the case/control analyses of ICH and ESRF, I initially used freely available, 
unscreened controls from the Wellcome Trust Case Control Consortium Phase 1.  
These consisted of 1500 samples from the 1958 British birth cohort (58BC) which 
were genotyped on the Illumina HumanMap 550k chip.  This is a less dense chip 
than the Illumina Human610-Quad which was used for the transplant patient 
samples, so there were some SNPs that did not have control genotypes and could not 
be analysed. 
In order to increase sample size of controls, and therefore power, and improve SNP 
coverage to match the transplant study genotypes, I carried out the same analysis 
using the WTCCC Phase 2 controls.  These controls consisted of 3000 58BC and 
3000 NBS unscreened individuals, each of which consisted of the original 1500 
controls genotyped for Phase 1 along with 1500 new samples.  These samples were 
genotyped on the Illumina Human670-Quad chip.  This chip is a slight upgrade to 
the Illumina Human610-Quad used for the KCL transplant patients, so the overlap 




Table 12. Data available for ESRF and ICH association studies 
Control Source ESRF  ICH  














Replication data was obtained from a cohort collected and genotyped by a team at 
the University of Newcastle.  The Newcastle (NC) cohort consists of 400 donors and 
439 recipients.  The 439 recipients were used as ESRF cases for replication, and the 
400 donors were used as controls.  One hundred and fifty-three of the donors died of 
an intracranial haemorrhage, and these were used as cases for ICH replication with 
the remaining donors as controls.   
4.3 Methods 
4.3.1 Quality Control - Principal Components Analysis 
My contribution to the quality control procedures in this study was to carry out a 
principal components analysis (PCA) to identify non-Caucasian samples.  I received 
a data set that had been partially checked for quality control measures using standard 
 107 
QC techniques.  Thresholds applied for SNPs were missingness greater than 2%, 
HWE p-values less than 10-4 and minor allele frequencies less than 1%, resulting in 
the removal of 67748 SNPs.  Thirty-eight individuals were removed for sample 
missingness (5%), phenotype/genotype sex discordance and duplicated samples.  
After QC had been carried out to this stage the data set was pruned using linkage 
disequilibrium (LD) to a smaller set of SNPs.  For the purposes of genetically 
distinguishing between ethnic groups a reduced set of SNPs is adequate, and this 
reduction is generally done by thinning out the data to a set of SNPs with low LD.  
For this work I was given the file with QC applied as above, and LD-pruned using 
PLINK.  This pruning process in PLINK compares SNPs within a window of a user-
specified size, which in this case was 1500BP.  After checking within the first 
1500BP of a chromosome the window 'slides' along by another user-specified 
amount- in this case 150 BP - and checks LD again.  This sliding window continues 
along until the end of the chromosome.  The r2 threshold used for this data was 0.20, 
so one SNP from each pair of SNPs that are within 1500BP of each other, and with 
an r2 of greater than 0.20, was removed.  The resulting LD-pruned file had 80760 
SNPs in it. 
In order to identify samples from non-Caucasian populations I merged the renal 
transplant samples with data from the HapMap project (International HapMap 
Consortium, 2003).   I used all available unrelated samples from the CEU (Utah 
residents of European ancestry), YRI (Yorubans from Ibadan, Nigeria), JPT 
(Japanese from Tokyo, Japan) , CHB (Han Chinese from Beijing) and GIH (Gujarati 




Table 13. HapMap samples used in PCA for population stratification 







The data sets were merged only on the SNPs that were common between all HapMap 
samples and the renal transplant samples.  This left a total of 58035 SNPs for the 
PCA. 
The PCA was run in R and eigenvalues and eigenvectors were extracted using the 
eigen() function.  Given that there are 4 ethnic populations in our data, the majority 
of the genetic differences due to population differences should be accounted for in 
the first 3 PC axes.  The plots in Figure 7 illustrate the ethnic group to which the 
renal samples (light blue) belong by plotting PC1 vs PC2 values (top) and PC1 vs 
PC3 values (bottom). Each dot on this plot represents a single sample. A small 
number of the renal samples (light blue dots) clearly overlap or move towards a 
population other than CEU.  The CEU samples are difficult to see but they are black 
circles clustered under the majority of the renal samples near the bottom-centre of 




Figure 7. First 3 PC axes of PCA for population stratification 
 
The aim of this PCA was to identify and remove samples from people who were not 
Caucasian, and this was done by setting thresholds for PC1, PC2 and PC3 that tightly 
surrounded the CEU samples, and the renal samples which overlap them.  Any renal 
samples which did not meet these thresholds were then removed from further 
analysis.  I set thresholds of PCA1 scores < 0.01 and PCA3 scores <0.02 for 
inclusion in the GWAS. Thirty-two samples did not meet these criteria and were 
removed for having non-Caucasian ancestry. 
4.3.2 End Stage Renal Failure, Acute Rejection and Intracranial 
Haemorrhage 
These three studies were all carried out as standard case/control analyses using 
PLINK.  This performs a chi-square test of association between allele counts at each 
SNP and case/control status.  The results consist of p-values for each SNP indicating 
the significance of the finding, along with odds ratios for the 2x2 contingency table.  























































4.4.1 End Stage Renal Failure 
On analysis with the WTCCC1 controls, two of the ESRF p-values were far smaller 
than any others (rs10053502, p-value=1.86E-51 and rs361147, p-value=5.11E-38, 
see Figure 8 top plot).  No other SNPs near these two showed evidence of 
association, which is normally seen because of  LD. On contacting Illumina we 
found that some SNPs showed large differences in allele frequencies when 
genotyped on the Human610-Quad chip (renal samples) and the HumanMap 550k 
chip (WTCCC1 controls).   
 
Figure 8 Plots of p-values from ESRF analysis using WTCCC1 controls  
Results shown before (top) and after (bottom) removal of 2 SNPs for confirmed platform 





We obtained a list of these SNPs and our top two were in this list.  We therefore 
removed these two SNPs and re-examined the results (see Figure 8 bottom plot). 
The results of the association study using the larger set of WTCCC2 controls are 
given in Figure 10. The top figure shows a cloud of SNPs above the majority of the 
plotted SNPs which have very small p-values.  However, as with the top two SNPs in 
the analysis with the WTCCC1 controls, there are no neighbouring SNPs showing 
association signals and thus no 'towers' common with real association signals. Given 
the very low p-values for the SNPs in this cloud, it would be very unusual if no other 
SNPs in the region of any of these 30 SNPs showed any association signal at all.  
These SNPs were not on the list of SNPs given to us by Illumina, however we 
believe these to be false signals due to differences in the platforms (610Quad and 
670Quad), and we relayed this information to Illumina.  A corrected plot with this 
cloud of SNPs removed is also given in Figure 10. 
 
Figure 9. Cluster plot of rs1551821 showing poor clustering an genotype calling 
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The remaining top SNP association on chromosome 18 was an isolated SNP showing 
no 'tower' of nearby associations. Singleton associations such as this raise concerns 
over genotyping.  Examination of the cluster plot (see Figure 9) showed that this 
SNP had not been called properly, and this SNP was not replicated.  
 
Figure 10. Plots of p-values from ESRF analysis using WTCCC2 controls  
Results shown before (top) and after (bottom) removal of 2 SNPs for confirmed platform 
discrepancies.  Note different scale on the y-axis. 
After removing the SNPs that were believed to be false association signals due to 
platform differences and the SNP that was poorly genotyped, the remaining top 
SNPs from the analysis with WTCCC1 and WTCCC2 controls were genotyped in 
the Newcastle replication samples.  The results of the replication analyses using 





Table 14. Association (KCL vs WTCCC controls) and replication (Newcastle recipients vs 
donors) p-values for ESRF 




rs874838 2 85275202 6.52E-06 0.3729 
rs2289959 2 136140374 8.08E-06 0.7278 
rs309152 2 136373722 8.10E-06 0.3239 
rs16829355 2 149306740 5.59E-06 0.8894 
rs950266 3 57324905 3.82E-06 0.8366 
rs4484262 4 89158024 1.32E-08 0.9397 
rs10014233 4 186017111 5.00E-07 0.6108 
rs2786714 9 103624285 5.60E-06 0.3383 
rs704018 10 80291027 2.33E-06 0.2051 
rs10500537 16 65160772 6.73E-07 0.5028 
rs8074821 17 71804694 4.19E-05 0.6252 




4.4.2 Acute Rejection 
The Manhattan plot of recipients with biopsy-confirmed definite AR vs recipients 
with unconfirmed AR or no record of AR is given in Figure 11.   
 
Figure 11 Association p-values for KCL recipients with at least one acute rejection episode in 
the first twelve months post-transplantation 
Data uses KCL recipients who did not have an AR as controls. 
 
Table 15 P-values of top associations for Acute Rejection 
SNP Chr Position P-value 
rs7431637 3 144532459 4.83E-06 
rs4839628 3 144569015 3.08E-06 
rs17051344 4 122504713 1.88E-05 
rs3759 6 15405889 1.42E-06 
rs7951530 11 24203480 2.11E-05 
rs12324075 15 98690270 6.63E-06 
rs1401197 16 78895134 6.75E-07 
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SNP Chr Position P-value 
rs3098599 16 79371197 7.17E-06 
rs11865270 16 87183002 3.41E-07 
rs114607 22 38706329 5.29E-06 
 
Acute rejection phenotype information was not available at the time of analysis for 
the Newcastle recipients. This data is available from NHSBT, however we did not 
ask for it at this stage as we asked for all phenotype and covariate data for all UK 
transplants at a later date, for the WTCCC3 study described in the next chapter.  As a 
result replication of these associations was not attempted at the time of analysis. 
4.4.3 Intracranial Haemorrhage 
For the analysis of donors who died of ICH, we used the same WTCCC1 and 
WTCCC2 controls as we used in the ESRF study.  The platform differences are 
again apparent, giving spurious association signals for 2 SNPs using the WTCCC1 
controls and 29 SNPs using WTCCC2 controls.  Plots of the p-values from these 
analyses, before and after removal of the spurious associations, are given in Figure 
12 and Figure 13. 
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Figure 12 Association p-values for ICH using WTCCC1 controls  
Data represents before (top) and after (bottom) removal of SNPs showing spurious association 




Figure 13 Association p-values for ICH using WTCCC2 donors  
Data represents associations before (top) and after (bottom) removal of spurious association 
signals. 
 
The cloud of spurious associations from the WTCCC2 controls is 30 SNPs in the 
ESRF study, and 29 of those form the cloud in the ICH study. The 30th SNP in the 
ESRF cloud is rs855523 on chromosome 9.  Although the p-value for this SNP in 
ICH is not in our cloud, it still a very small p-value at 3.543x10-5. It is unlikely that 
this SNP would have such a low p-value for both of these phenotypes, so we 
assumed that this was also due to genotyping problems and did not attempt to 
replicate it. 
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Replication of the top hits from the ICH study was unsuccessful. The power of the 
replication study is very low; even lower than for ESRF, with only 153 cases of ICH.  
We can't conclude whether or not the top hits in the discovery analysis are false 
positives or true associations that didn't replicate due to lack of power in replication. 
Table 16. ICH SNPs with discovery and replication p-values 




rs9428851 1 238790962 5.38E-06 0.3041 
rs6714431 2 168885012 5.79E-06 0.0692 
rs9854823 3 121633974 1.29E-05 0.5158 
rs1288569 4 186467270 1.15E-05 0.0783 
rs1283726 8 108545032 8.46E-06 0.8106 
rs2227564 10 75343107 9.89E-05 0.8393 
rs17271583 12 19334811 1.27E-05 0.8854 
rs17506327 13 101942907 2.01E-06 0.8402 
rs2581717 18 66234261 5.05E-06 0.8287 
rs6099111 20 54370639 1.85E-06 0.5752 
rs6626447 X 144741334 1.17E-06 0.2937 
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4.5 Discussion & Conclusions 
ESRF replication was unsuccessful with 439 cases and 400 controls.  The power of 
the replication study is not very high and this may mean that true associations would 
not be found. 
Table 17. Examples of power to detect associations. 
These examples are for a disease with 2% prevalence and odds ratio of 1.3 (for the minor allele), 
and assuming the causal SNP (or a SNP in perfect LD) is tested. 
Sample Size 
(Case/Control) 
















Given the small sample sizes in both cohorts, false positives in the discovery cohort 
and lack of power to detect effects in the replication are both possible, and it is 
difficult to say which is more likely without a larger study.  In the next chapter I 
describe the WTCCC3 renal transplant dysfunction study which was carried out as 
an extension to this study, in order to try to increase power to confirm these 
associations and find new ones. 
None of the 'cloud' SNPs were on the Illumina list of problem SNPs between 
platforms.  Given that the same SNPs are showing these signals in two unrelated 
phenotypes, and none of them have any other nearby SNPs showing the usual 'tower' 
of associations from SNPs in LD, we concluded that these are also SNPs with 
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genotyping problems between the two platforms and reported our findings to 
Illumina. 
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5 WTCCC3 Study in Renal Transplantation 
Dysfunction 
In this chapter I describe a genome-wide association study in renal transplant 
dysfunction (RTD) funded by the Wellcome Trust Case Control Consortium and led 
by a management team at King's College London.  The study was based on the 
design of the renal transplantation GWAS described in Chapter 4 and includes the 
samples genotyped for that project, along with further samples from multiple centres 
and clinical data from NHS Blood and Transplant (NHSBT). 
In this chapter I will present several pieces of work I have carried out using the data 
in this study: 
1. Analysis of the primary time-to-failure phenotype, including a preliminary 
covariates analysis. 
2. End-stage renal failure (ESRF) and intracranial haemorrhage (ICH) binary 
phenotype analysis using logistic regression. 
3. Application of SNPHarvester to search for interactions. 
4. An adaptation of the SNPHarvester programme which will use the time-to-
event data instead of transforming to a binary phenotype. 
5.1 Introduction 
The aim of this project, as with the smaller King's College London pilot study, was 
to search for genetic variants that affect the long-term prognosis of a transplanted 
kidney.  The design of this study was slightly different to the design of the pilot 
study.  Stricter inclusion and exclusion criteria were applied, and samples were 
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contributed by a large consortium consisting of many transplant centres around the 
United Kingdom and Ireland. Phenotype and covariate data was collected for all UK 
transplants from NHSBT.  Information about the Irish transplant patients was 
obtained directly from the Irish collaborators.  I carried out a comprehensive analysis 
of all of the data collected on the donors, recipients and transplants to identify 
covariates that would help to establish the baseline hazard for the survival function.  
These covariates were then included in the survival model to search for SNPs that 
were significantly associated with survival time of the graft. 
The results of the methods comparison in chapter 3 showed that SNPHarvester was 
the most successful method for finding the previously identified statistical interaction 
in psoriasis.  I applied this method to the RTD data by transforming the survival 
phenotype into 3 binary phenotypes - survival at 3 years, 5 years and 10 years.  
5.2 Contributions 
The work outlined in this chapter is a part of a large collaborative effort.  I am one of 
the analysts on this project, and we have divided the work in some cases, and in 
others we have duplicated efforts to ensure correctness.  In Table 18 I list the work 
that is presented in this chapter and specify who has done it, with JM referring to 
myself and CF referring to our collaborator Chris Franklin.  In some cases, 
particularly in the QC, the work was not carried out by me but I feel it is important to 




Table 18. Division of analysis work 
Work Analyst(s) 
QC of 4 separate cohorts & all file merging CF 
PCA for population stratification CF, JM 
Covariates Analysis JM 
Survival Analysis (all models) CF, JM 
SNPHarvester application and development work JM 
  
5.3 Genotypes, Phenotypes and Covariates 
Genotyping of the majority of the samples for this study was carried out at the 
Wellcome Trust Sanger Institute on Illumina Quad660 chips.  A further set of 
samples were previously genotyped for the KCL pilot study on Illumina Quad610 
chips (see Chapter 4).  The transplant centre in Dublin had previously genotyped a 
cohort of transplant recipients, and we included this data in our study.  The matching 
donors from Dublin were then genotyped as a part of the main cohort at the Sanger 
Institute.  These cohorts will be referred to for the remainder of this chapter as 
Dublin (Dublin recipients only, genotyped in Dublin), KCL and Sanger (remaining 
Dublin samples genotyped at the Sanger). 
We obtained the phenotype information, along with several clinical measures, from 
NHSBT on 4th May 2012.  The time-to-graft-failure is measured from the date of 
transplantation and an event is recorded if the patient is lost to follow-up, if their 
kidney fails or if the study period ends without the failure of the kidney.  For our 
purposes the end of the study period is the date of data extraction by NHSBT, 4th 
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May 2012.  The last recorded event before this time is therefore examined and 
classified as a failure event or a censored event. 
A kidney failure event is defined in a number of ways: 
1. Return to dialysis 
2. Re-transplantation 
3. Return to transplant waiting list 
Any transplanted kidneys that were still functioning at the last recorded follow-up 
date were considered to be censored. In this case the time of last known follow-up 
was recorded, and the event type was censored.  
5.3.1 Inclusion and exclusion criteria 
We applied inclusion and exclusion criteria to the selection of samples for 
genotyping, to maximise the information that could be extracted from the available 
transplants.  These criteria are given in Table 19. Selected data on each transplant 
was gathered from the transplant centres providing the DNA samples as well as from 
NHSBT.  The data collected from the centres was primarily used to ensure proper 
identification of donors, recipients and transplants, so the NHSBT clinical data could 
be matched to the correct samples.  Transplant centres which provided DNA also 
provided us with, at a minimum, NHSBT transplant ID, date of transplant, date of 
birth of recipient and gender of recipient.  Data extracted from NHSBT also included 
these values, and any instances where the dates and genders did not match up could 
then be followed up to ensure correct identification of samples.  If there was any 
ambiguity the donor and recipient samples were not genotyped and the transplant 
event was not included  in the analysis. 
 125 
Table 19. Inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
Cadaveric donors only 
Donor and recipient DNA 
available 
Transplant date before 1/9/06 
 
Age of recipient < 18 years 
Recipient had failure event within 3 months of 
transplant 
 Recipient had no kidney failure event AND the 
date of the last recorded event is less than three 
years from transplant date (follow-up of less 
than 3 years)  
Any transplant type other than single kidney 
only 
 
5.3.2 Whole-genome amplification 
Some of the DNA samples sent to us for this project did not contain enough DNA for 
genotyping.  In order to increase numbers as much as possible we carried out whole-
genome amplification on these samples prior to genotyping.  This was also carried 
out at the Sanger Institute.  This set of samples will be referred to as the WGA 
cohort, and together with the Sanger, KCL and Dublin cohorts make up all of the 




5.3.3 Survival-related phenotypes 
1. Date of transplant 
2. Date of first re-transplant, if occurred 
3. Date of first reinstatement on to transplant waiting list, if occurred 
4. Date of first transfer back to dialysis, if occurred.   
5. Date of last event recorded on the database 
6. Last event type:  Still living / death 
7. gsurv - graft survival, in days 
8. gcens - gsurv event type; (1=censored, 2=graft failure event) 
The first 6 pieces of information allow us to calculate the survival time, in days, of 
the graft, or the time to censoring, to check the values for gsurv and gcens that were 
given to us by NHSBT.  Note that we assume that death preceded by dialysis is due 
to loss of graft function, and this is counted as a graft failure event.  Death NOT 
preceded by dialysis is considered a censored event.   
5.3.4 Clinical data 
The clinical data available for this study is summarised in the following tables. Table 
20 and Table 21 summarise the numeric and categorical variables respectively, and 
include the number of missing values. Table 22 shows the drug treatments for the 
recipients at transplantation, 3-months and 12-months after transplantation. Table 23 
lists the number of transplants carried out at each centre. 
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Table 20. Summary of numeric clinical variables 
Variable Mean (range)  Missing 
Age of donor at death/transplant 42.69 (1-81) 0 
*Age of recipient at transplant 45.62 (16-79) 0 
Serum creatinine at 3 months (µmol/l) 157.1 (55-872) 1143 
SC 12 months 153.5 (56-992) 998 
SC 24 months 156.3 (52-854) 1220 
SC 36 months 159.4 (55-934) 1245 
SC 48 months 160.1 (51-836) 1427 
SC 60 months 158.5 (53-862) 1704 
Cold ischaemic time (CIT) in minutes 1151 (0-3180) 1362 
*One recipient in the NHSBT data was 16 years old, which is below our threshold of 18.  The 
samples from this transplant were not genotyped and it was not included in any further analyses 
 
Table 21. Summary of categorical clinical variables 
Variable Factor level counts Missing 
Sex of donor (male/female) Male: 2039 
Female: 1619 
1 




Variable Factor level counts Missing 





Graft number  1: 3251 
2+: 408 
0 
Diabetes  Yes: 201 
No: 2729 
729 
Type of transplant Kidney only: 3630 
**En-bloc kidney: 3 
**Kidney & pancreas: 20 
0 











Variable Factor level counts Missing 





Blood group mismatch No: 3063 
Yes: 176 
420 
Donor type Heart beating: 3417 
Non-heart beating: 242 
0 





Primary renal disease 58 categories with 1-343 in 
each  
1685 
HLA mismatches at A,B,DR 27 categories with 4-983 in 
each 
0 
Acute rejection 12 months (derived 




**Not genotyped and removed from further analysis as the study is limited to kidney-only 
transplants 




The type of transplant and recipient ethnicity are included only to check that they are 
correct.  Transplant type should always be kidney-only and recipient ethnicity should 
always be Caucasian.   
Table 22. Frequencies of patients on different drugs at transplant, 6 months and 12 months 
Drug and treatment time No Yes Missing 
Azathioprine - transplant 1340 981 1338 
Azathioprine - 3 months 1403 961 1295 
Azathioprine - 12 months 1488 974 1197 
ALG induction - transplant  2252 66 1341 
Cyclosporin - transplant 995 1329 1335 
Cyclosporin - 3 months 1224 1178 1257 
Cyclosporin - 12 months 1394 1132 1133 
Mycophenolate - transplant 1349 969 1341 
Mycophenolate - 3 months 1074 941 1644 
Mycophenolate - 12 months 1151 837 1671 
Other - transplant 1391 922 1346 
Other - 3 months 2008 261 1390 
Other - 12 months 1995 347 1317 
OKT induction - transplant  2310 8 1341 
Prednisolone - transplant 375 1949 1335 
Prednisolone - 3 months 340 1818 1501 
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Prednisolone - 12 months 466 1783 1410 
Tacrilomus - transplant 1373 948 1338 
Tacrilomus - 3 months 1028 995 1636 
Tacrilomus - 12 months 965 1024 1670 
Steroids - 3 months 28 193 3438 
Steroids - 12 months 26 234 3399 
 
Table 23. Number of transplants carried out at each participating transplant centre 









London, Royal Free 11 
London, Royal London 96 
London, Guy's 367 
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London, WLRTC 9 
Cardiff 361 
 
The tables above show that there was a great deal of missingness in the clinical data.  
Some of this is due to having less information from certain centres. Table 24 shows 
missingness for 3 variables by centre.  Dublin in particular is missing quite a lot of 
data for some phenotypes. Dublin is not part of NHSBT and we requested the data 
from them directly.  Our original request for data from Dublin and NHSBT was a 
reduced set of covariates which were easy to retrieve quickly and were known to be 
complete and reliable in the NHSBT database.  They were also sensible clinical 
measures that may have an effect on a transplanted kidney.  We later made a request 
for further clinical data but much of this data could not be provided by Dublin.  The 
extra data was sent by NHSBT but the Belfast transplant centre was mistakenly left 
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out of this additional data set.  The inclusion of any of these extended clinical 
variables in our survival modelling would have resulted in either the removal of all 
Dublin and Belfast transplants from the study or would have required estimating the 
missing data. This is often done by using the mean, median or mode depending on 
the type and distribution of the data.  While this is a reasonable approach in some 
circumstances, it is probably not wise to do this for all of the transplants from a 
centre.  We therefore proceeded with the analysis on the original smaller set of 
covariates which were available for all transplant centres including Belfast and 
Dublin.  
Table 24. Total transplants by centre and missing data for selected phenotypes 
Centre 
Total 





Newcastle 184 27 0 50 
Leeds 368 1 0 65 
Dublin 447 311 309 78 
Leicester 114 7 0 23 
Nottingham 10 0 0 0 
Sheffield 77 0 0 4 
Belfast 420 420 420 420 
Cambridge 76 0 0 3 
Royal Free 11 1 0 0 









Guy's 367 84 0 133 
St George's 125 0 0 21 
Portsmouth 29 0 0 4 
Oxford 171 45 0 65 
Plymouth 67 0 0 3 
Birmingham 227 115 0 86 
Coventry 41 12 0 4 
Liverpool 42 0 0 1 
Manchester 258 1 0 14 
Glasgow 159 143 0 35 
WLRTC 9 2 0 0 
Cardiff 361 170 0 102 
 
5.4 Genotype Quality Control 
Genotype quality control procedures for this study were somewhat more complicated 
than normal due to genotyping taking place in four different groups.  QC was carried 
out on each of the 4 cohorts individually before genotypes were merged, and one 
final check was carried out to ensure the genotypes and samples in the merged set 
passed all QC criteria.  Most of the work on the QC was carried out by the lead 
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analyst at the Sanger Institute (See Table 18), but the results are presented here for 
completeness.  
5.4.1 Quality Control Thresholds and Results 
The first step in the QC was to exclude SNPs for low call rates (see Table 25. Initial 
screening of SNPs with low call rates).  This is a fairly generous threshold, and 
another more strict threshold was applied after sample QC.  This was done first, 
before sample call rates were calculated, so that missingness at very bad SNPs did 
not push samples with borderline call rates over the threshold for removal.   
Table 25. Initial screening of SNPs with low call rates 
 Sanger WGA KCL Dublin 
Number of samples 3728 990 1201 365 
Number of pre-QC SNPs 594398 578723 562831 599011 
SNP call rate < 95% 4992 15675 2855 590477 
*After merging QCed data sets 
The next stage of QC was to calculate sample (e.g. individual) statistics and remove 
those not passing our thresholds. These results are given in Table 26. At this stage a 
PCA was run on each LD-pruned cohort, including HapMap samples from 
continental ethnic groups JPT, CHB, GIH, YRI and CEU.  Samples showing genetic 




Table 26. QC results on samples 
 Sanger WGA KCL Dublin 
Number of samples 3728 990 1201 365 
Number of SNPs  
(after SNP call rate 
exclusions) 
589406 563051 559976 590477 
Sample call rate <98% 35 160 37 5 
Heterozygosity outliers  
(3sd) 











IBD>0.1 87 13 167 17 
PCA for ethnicity 78 20 54 10 
Gender mismatch 18 24 6 1 
*After merging QCed data sets 





Table 27. QC results on SNPs 
 Sanger WGA KCL Dublin 
Number of samples 3501 702 1201 **192 
Number of SNPs  
(after call rate exclusions) 
589406 563051 559976 590477 
SNP Call rate <98% 7916 25088 3841 13093 
HWE p-value < 1x10-6 9975 9100 2039 5562 
MAF < 0.01 29392 27404 18165 24530 
Non-random missingness 6642 5813 1376 1132 
*After merging QCed data sets 
**333 samples passed sample QC, 192 of these had required phenotype info 
The final numbers of SNPs and samples from each cohort that passed QC, along with 
the final combined numbers, are given in Table 28.  These are the final numbers of 
SNPs and samples that will be available for analysis. 
Table 28. SNPs and samples passing QC from each cohort 
Cohort SNPs  Samples 
Sanger 546055 3501 
WGA 522274 702 
KCL 538050 1201 
Dublin 563011 192 
Total 512535 5596 
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5.4.2 PCA for Identifying Cohort differences 
After merging the four cohorts, a PCA without the HapMap data was carried out to 
identify systematic differences from other sources.  Our main aim was to identify and 
correct for any differences due to genotyping four separate cohorts.  We plotted PCA 
results, colouring the samples by cohort (Figure 14).  
PC1 is clearly separating the KCL and Dublin samples, while PC4 shows some 
separation of the WGA samples from the other three cohorts.  PC5 - PC8 do not 
seem to correlate with cohort labels.  PC2 is pulling a small number of KCL and 
Sanger samples away from the rest, while PC3 spreads some of the Sanger and WGA 
samples out slightly.  PC2 did not separate samples by cohort, but we believed it may 
be due to some residual population stratification that was not excluded by the 
thresholds applied to the cohorts during QC before merging.  We excluded further 
samples along this axis at a threshold of -0.1.  
 139 
 
Figure 14. PCA axes 1-8 coloured by cohort. 
 
5.5 Methods 
5.5.1 Merging data from WGA samples 
Genotype data from the WGA samples had to be merged with the non-WGA samples 
before analysis.  WGA genotypes were first merged with the Sanger cohort, as these 
had been genotyped at the same location on the same chips, reducing potential 
sources of variability.  This work was carried out by the lead analyst at the Sanger 
institute, but I present the main findings and the decisions we took as a result. 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































There were two options for merging the WGA and Sanger cohorts.  Intensity data 
was available for all samples from these cohorts, so it was possible to merge the 
genotypes at the intensity level and recall the genotypes together.  The genotypes 
were also called independently so it was also possible to merge the data at the 
genotype level.  Merging two different data sets could cause spurious associations or 
an overall deflation of p-values if there are systematic differences between the 
cohorts.  In order to determine the best way to merge the data it was done both ways, 
then we carried out pseudo case/control analysis using the WGA cohort as cases and 
the Sanger cohort as controls.  The transformed (-log10(p)) p-values were then 
examined for a departure from the distribution of expected values. The results shown 
in Figure 15, indicate a larger inflation of the test statistic when merged at the 
intensity level. Additionally, the number of samples removed for QC failures was 
higher when merging intensities and calling the data together.  Called separately, a 
sample missingness threshold of 98% resulted in 34 genomic and 138 WGA samples 
being removed, for a total of 172 samples.  Called together, the same threshold 
removed 241 samples.  In order to retain as many samples as possible and avoid a 
deflation of p-values due to differences in genotyping, we decided to merge the 
genotypes rather than merge the intensities and re-call genotypes.  All work 
presented in this thesis, including the previously-presented QC results, is based on 




Figure 15. QQ plot from two pseudo-association studies  
WGA and Sanger samples after merging data at the intensity level and re-calling genotypes 
(top) and calling genotypes separately and merging at the genotype level (bottom). 


































5.5.2 Covariates Analysis 
Given the high level of missingness of some of the clinical data, we included only 
covariates that were complete or nearly complete in the analysis of covariates (see 
Clinical data).  In some cases, clinical data that may be important but was left out of 
the model due to missing data can be checked on after the analysis; for example any 
hits in the survival analysis can be checked against SNPs known to be associated 
with diabetes or acute rejection, to see if there is any overlap.   
The final form of the analysis of the covariates is given in Equation 13. 
Equation 13. Model as fit to covariates using Cox Proportional Hazards modelling. ℎ! 𝑡 =   exp  (𝛼 𝑡 + 𝑅𝑒𝑐𝑖𝑝_𝑐𝑡 + 𝐺𝑟𝑎𝑓𝑡𝑛𝑜 + 𝑅𝑎𝑔𝑒 + 𝐷𝑎𝑔𝑒 + 𝑅𝑠𝑒𝑥 + 𝐷𝑠𝑒𝑥) 
where Recip_ct is the transplant centre where the recipient received the kidney, 
Graftno is the number of transplants the recipient has received (including present), 
Rage is recipient age, Dage is donor age, Rsex is recipient sex and Dsex is donor sex. 
Kaplan-Myer plots for covariates were also generated to be examined for any 
groupings of factors. 
Results for the survival analysis of covariates are presented in a table, each row of 
which shows the coefficient ß for each numeric variable or single level of a factor, 
the exponential of ß, its standard error, a z-score and a p-value for the z-score.  
Taking the exponential of the coefficient gives the relative risk (RR). For a factor 
this is the risk relative to a reference group, with the reference group having a hazard 
of 1.  If exp(ß) is higher than one, this is an increase in the hazard, and the 
interpretation for a factor is that the group is at increased risk relative to the reference 
group, and is more likely to fail sooner.  For example if exp(ß) is 1.5, transplants 
from that group are 1.5 times more likely to fail at any given time t than transplants 
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from the reference group.  For the transplant centre the reference group is A1313, 
which is the centre with the median survival time.  Recipients on their first transplant 
are the reference group for the graft number covariate (GRAFT_NO), and all others 
(on their 2nd, 3rd and 4th transplant) are grouped together into the group "2+".  Dsex 
and Rsex represent the change in survival time for females (group 2) relative to 
males.   
For numeric variables the exponential of the coefficient represents the effect on 
survival time for every increase of 1 in that variable.  For example, with donor age, 
exp(ß) represents the increase in risk of failure for each increase in age of one year. 
For example, if exp(ß) is 1.05, a transplant with a donor of age 30 at time of death is 
5% more likely to fail at any time than a transplant from a donor who is 29 at the 
time of death.   
All survival models were fit using the software package R version 2.15.0 (R 
Development Core Team, 2011), using the survival package version 2.36-1 
(Therneau and Lumley, 2011).  
5.5.3 Survival Analysis of Genotypes 
I carried out a survival analysis using the genetic data by fitting a Cox Proportional 
Hazards model as I did with the covariates analysis.  For this analysis I want to test, 
for each SNP, a recipient effect, a donor effect, and an interaction effect, all at the 
same SNP. A full Cox model for a single SNP is shown in Equation 14. 
Equation 14. Full Cox Proportional Model for a single SNP ℎ! 𝑡 =   exp  (𝛼(𝑡)+ 𝜷𝟎𝐶𝑂𝑉 + 𝛽!𝑆𝑁𝑃1𝑅 + 𝛽!𝑆𝑁𝑃1𝐷 + 𝛽!𝑆𝑁𝑃1𝑅 ∗ 𝑆𝑁𝑃1𝐷) 
 144 
where t is time in days, α(t) is the baseline hazard function (incorporating the 
intercept), ß0  is the set of coefficients for the covariates, ß1 is the effect of the 
recipient genotype, ß2 is the effect of the donor genotype, and ß3 is the interaction 
effect between donor and recipient genotype.  In this model the unit of analysis is the 
transplant, so in the model above, the locus for SNP1R and SNP1D is the same, but 
the people contributing genotypes for each are different; they are the donor and the 
recipient contributing to the same transplant. 
When designing the study every attempt was made to identify transplants in which 
both donor and recipient DNA was available along with the required phenotypes and 
covariates. In some cases the transplant event was missing a donor or a recipient, due 
to individuals removed for quality control issues. If donor and recipient effects with 
all covariates were fit and tested in the same model, then only the intersection of 
samples with donor and recipient genotypes could be used for all effect estimations.  
In order not to waste data, the models were fit separately for each effect so that, for 
example, a transplant event whose donor was not genotyped would not be eliminated 
when estimating the recipient effect.  In Equation 15 below, Model 1 uses all 
samples with recipient genotypes available and calculates coefficients and p-values 
for recipient effects at all SNPs.  Model 2 uses all samples with donor genotypes 
available and calculates coefficients and p-values for all SNPs.  Model 3 includes 
only samples with both donor and recipient genotypes available, and again calculates 




Equation 15. Single-SNP regression for transplant data showing the a) recipient-only model, b) 
donor-only model and c) full interaction model 𝑎)  ℎ! 𝑡 =   exp  (𝛼(𝑡)+ 𝜷𝟎𝐶𝑂𝑉 + 𝛽!𝑆𝑁𝑃1𝑅) 𝑏)  ℎ! 𝑡 =   exp  (𝛼(𝑡)+ 𝜷𝟎𝐶𝑂𝑉 + 𝛽!𝑆𝑁𝑃1𝐷) 𝑐)    ℎ! 𝑡 =   exp  (𝛼(𝑡)+ 𝜷𝟎𝐶𝑂𝑉 + 𝛽!𝑆𝑁𝑃1𝑅 + 𝛽!𝑆𝑁𝑃1𝐷 + 𝛽!𝑆𝑁𝑃1𝑅 ∗ 𝑆𝑁𝑃1𝐷) 
The significance of the term of interest is then estimated by dropping the term to be 
tested and carrying out a 1 degree of freedom likelihood ratio test between the two 
models.  For models one (recipient) and two (donor), the SNP coefficient is dropped 
to leave only the baseline hazard and the covariates.  In model 3 (full interaction 
model) the interaction term is dropped, leaving the baseline hazard, covariates and 
main effects in the model. 
5.5.4 Application of SNPHarvester to binary survival phenotype 
In its published form, SNPHarvester runs on case/control phenotypes only (see 
Chapter 2).  In order to apply SNPHarvester to the data from this renal transplant 
dysfunction study, I transformed the data to 3 different binary phenotypes; 3, 5, and 
10-year survival.  For each of these, any graft failure events occurring before the 
specified time threshold were considered cases, and any grafts that definitely 
survived until that time were controls.  Any transplants that had a censored event 
time before the time threshold were dropped from the analysis, as it was not possible 
to allocate them with certainty to the case or control group.  This produced three 
case/control data sets, each of which had a different number of cases, controls, and 
total samples (see Table 29).  The three-year survival phenotype had the largest 
number of total samples but the smallest number of cases.  As time moves on, more 
 146 
failure and censoring events occur, which results in a larger number of cases but a 
smaller total number of samples.  
Table 29. Binary survival phenotype case/control counts 
Phenotype Cases Controls Total 
3-year survival 155 1920 2075 
5-year survival 268 1585 1853 
10-year survival 449 540 989 
 
I ran SNPHarvester on these data sets with the stopping criteria numsuccessiverun=5.  
This means that if the algorithm creates a path through the entire data set 5 times 
without any pairs of SNPs exceeding the p-value threshold, the process will 
terminate. 
5.6 Results 
5.6.1 Covariates Analysis 
The table of results from the survival analysis on the covariates is given in Table 30. 
For this analysis there were 961 failure events from a total of 3658 transplants.  
Table 30. Covariates analysis results 
Variable/Level ß  exp(ß)   se(ß)       z Pr(>|z|)     
RECIP_CT/B6313 -0.062 0.940 0.195 -0.319 0.749 
RECIP_CT/BH 0.436 1.55 0.171 2.6 0.011* 
RECIP_CT/C0301 0.037 1.04 0.251 0.148 0.882 
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RECIP_CT/C0851 -0.432 0.649 1.01 -0.426 0.670 
RECIP_CT/C1201 -0.188 0.829 0.351 -0.535 0.592 
RECIP_CT/CH 0.663 1.94 0.172 3.842 1.22E-04*** 
RECIP_CT/D0101 -0.261 0.771 0.386 -0.676 0.499 
RECIP_CT/F0708 -0.304 0.738 1.01 -0.300 0.764 
RECIP_CT/F1212 0.091 1.096 0.275 0.332 0.740 
RECIP_CT/G1501 0.179 1.196 0.186 0.965 0.335 
RECIP_CT/H1305 -0.596 0.551 0.326 -1.827 0.068. 
RECIP_CT/J2102 0.414 1.51 0.385 1.08 0.282 
RECIP_CT/K4102 -0.307 0.736 0.242 -1.267 0.205 
RECIP_CT/L3395 -0.017 0.983 0.367 -0.047 0.963 
RECIP_CT/M1202 -0.187 0.830 0.208 -0.897 0.370 
RECIP_CT/M1701 0.258 1.29 0.316 0.816 0.414 
RECIP_CT/N2117 -0.031 0.969 0.436 -0.071 0.943 
RECIP_CT/P1101 0.076 1.08 0.203 0.373 0.709 
RECIP_CT/SG516 0.115 1.12 0.202 0.568 0.570 
RECIP_CT/T0701 0.232 1.26 0.724 0.321 0.748 
RECIP_CT/W7001 0.059 1.06 0.182 0.325 0.745 
GRAFT_NO/2+ 0.452 1.57 0.098 4.61 4.1E-06*** 
RAGE -0.003 0.997 0.003 -1.30 0.192 
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DAGE 0.020 1.02 0.002 8.75 <2e-16*** 
RSEX/2 0.086 1.09 0.066 1.29 0.197 
DSEX/2 -0.068 0.934 0.066 -1.04 0.300 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
Although there are several clinical variables significantly associated with graft 
failure times, the overall variance explained is only 4.3%.   
Transplant centres BH and CH are significantly different from the median A1313 
(not shown, RR=1).  Both of these have a higher RR than A1313.  H1305 has a 
lower RR with a marginal p-value of 0.07.  A Kaplan-Meier plot of survival time by 
centre is given in Figure 15. Recipients who have received at least one previous graft 
have a significantly higher RR (Figure 16), as do recipients who receive kidneys 
from older donors (Figure 17).  Donor and recipient sex have no effect on the time to 
graft failure (Figure 19).  Based on these results we decided to include centre as a 3-
group factor, with the groups associated with low, average and high survival times. 
BH & CH form the low group, H1305 is the high group, and the remainder of the 
centres are in a single 'average' group.  Another factor of two levels indicating if it is 
the recipient's first transplant was also included, along with donor and recipient age 
at transplant as a numerical covariate.  We included recipient age because although it 
is not associated with survival time in this analysis (Figure 18) other studies have 
found it to be important (Summers et al., 2010). 
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Figure 18. Kaplan-Meier plot of survival time by donor age, divided into three equal-sized 
groups. 
 


































 Figure 20. Kaplan-Meier plot of survival time by gender (donor-recipient). 
























































5.6.2 Survival Analysis 
The results of fitting the Cox proportional hazards model to the time-to-graft-failure 
phenotype with covariates (3-group transplant centre, donor age, recipient age, 
binary first transplant indicator and first 4 PC axes) are shown in Manhattan plots in 
Figure 21. Over all of the results for all three effects, there were no genome-wide 
significant results.  
 
Figure 21. Manhattan plot of results for survival analysis of graft failure phenotype 
 
Graft Survival - Recipient Effect
Graft Survival - Donor Effect
Graft Survival - Donor x Recipient Effect
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Table 31 Top SNP associations from survival analysis of graft failure 
Chr	   SNP	   P-­‐value	   n	   Effect	  
15	   rs11072010	   1.19x10-­‐7	   2686	   R	  
19	   rs7250100	   1.78x10-­‐9	   2690	   R	  
2	   rs1465804	   2.54x10-­‐7	   2686	   R	  
3	   rs4859121	   1.37x10-­‐6	   2202	   D	  
8	   rs4734914	   2.39x10-­‐6	   2204	   D	  
8	   rs7827856	   2.73x10-­‐6	   2202	   D	  
3	   rs922784	   5.22x10-­‐6	   2204	   D	  
8	   rs7002197	   9.78x10-­‐6	   2203	   D	  
3	   rs4859121 1.75x10-­‐5	   2202	   I	  
 
5.6.3 SNPHarvester 
The first run of SNPHarvester was on the 10-year survival phenotype, which 
included 449 cases and 540 controls.  This analysis did not produce any significant 
single SNP or SNP pair results.  Given the small of samples in the analysis, the 
power to detect any associations would be very low.  Additionally, there are no 
significant findings in the survival analysis, so it is unlikely that SNPHarvester 
would have found single-SNP associations that the survival analysis could not.  The 
five-year survival phenotype included 268 cases and 1585 controls.  The only finding 
suggested by SNPHarvester was a single SNP, rs3754949 (recipient), on 
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chromosome 2. This SNP had a recipient p-value of 0.551 in our single-SNP survival 
analysis. 
The three-year survival phenotype included 155 cases and 1920 controls for analysis.  
SNPHarvester selected 1558 SNP pairs with scores that exceeded the Bonferroni-
corrected threshold.  I examined the distribution of the chi-square test statistic to see 
if there was any evidence of strongly association pairs of SNPs.  This is a left-
truncated distribution because the information about the SNP pairs with test statistics 
lower than the left-hand threshold was not saved, and so is not plotted.  There are 
some SNPs at the top end of the distribution which are slightly separated from the 
group and this could possibly represent a set of strong interaction signals. 
 
Figure 22. Histogram of test statistics for SNP pairs selected by SNPHarvester. 
All test statistics are chi-square distributed with 8 degrees of freedom. 
The test underlying the SNPHarvester results is a chi-square test.  It is sensible to 
check for rare genotype combinations between the significant pairs, as it is not 
recommended to apply a chi-square test to contingency tables with cell values of less 
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than five.  A screen of the SNPHarvester results revealed that only 44 of the 1558 
SNP pair contingency tables had all cells with a value of more than five.  The 
remainder of the results must be regarded as untrustworthy as the chi-square test 
would not be appropriate.  Furthermore, 24 of the remaining 44 pairs involved at 
least one SNP that was a known copy number polymorphism (Dayem Ullah et al, 
2012).  This would likely lead to genotype calling problems.  The remaining 20 SNP 
pairs are given in Table 32.  None of these SNPs are previously published GWAS 
associations, and none of them are non-synonomous coding variants.  
Table 32. Location of Inteactions discovered by SNPHarvester 
X2(2d.f.)	   SNP1	   Chr	  1	   Position	  1	   SNP	  2	   Chr	  2	   Position	  2	  
89.2	   rs1888861	   1	   156797961	   rs9868633	   3	   169741291	  
90.37	   rs1888861	   1	   156797961	   *rs9846780	   3	   187095439	  
89.96	   rs1888861	   1	   156797961	   *rs1568302	   3	   187100520	  
91.7	   rs1888861	   1	   156797961	   *rs1518872	   3	   187121796	  
84.14	   rs1888861	   1	   156797961	   *rs13065558	   3	   187122532	  
83.26	   rs1888861	   1	   156797961	   rs709081	   3	   191446862	  
82.74	   rs1888861	   1	   156797961	   rs1923200	   6	   23651526	  
83.8	   rs1888861	   1	   156797961	   rs310409	   6	   81798503	  
85.32	   rs9870672	   3	   57404880	   rs3926405	   2	   106563295	  
92.46	   rs9870672	   3	   57404880	   #rs7582470	   2	   121575818	  
83.36	   rs9870672	   3	   57404880	   #rs895491	   2	   121578827	  
85.37	   rs9870672	   3	   57404880	   rs4557160	   3	   164747930	  
82.95	   rs9870672	   3	   57404880	   rs6449012	   4	   14317116	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X2(2d.f.)	   SNP1	   Chr	  1	   Position	  1	   SNP	  2	   Chr	  2	   Position	  2	  
84.17	   rs9870672	   3	   57404880	   rs9352851	   6	   81392952	  
83.65	   rs9870672	   3	   57404880	   rs960874	   10	   10491092	  
88.45	   rs9870672	   3	   57404880	   +rs1924507	   10	   10521475	  
88.96	   rs9870672	   3	   57404880	   +rs71003	   10	   119349761	  
89.06	   rs9870672	   3	   57404880	   rs4441549	   20	   6042852	  
83.87	   rs6461942	   7	   26485860	   rs11786417	   8	   133135790	  
82.73	   rs7185918	   16	   85901065	   rs987611	   18	   1306068	  
*Pairwise LD between these SNPs ranges from 0.85-0.98  
#Pairwise LD is 0.96 
+Pairwise LD is 0.98 
 
There are only 4 SNPs in the 'SNP1' column of Table 32.  Two of these appear in 
several rows, paired with several SNPs that are in high LD, indicating that the same 
association interaction signal is being picked up.  This further reduces the total 
number of signals detected to 15 interactions. 
 
5.7 Extension of SNPHarvester to Survival Data 
SNPHarvester in its published format takes binary phenotype data.  In order to make 
the best use of the data available in the renal transplant dysfunction study, I have 
worked on an extension to SNPHarvester to allow it to take time-to-event data.  At 
the heart of the original SNPHarvester is the idea of using a score test to quickly 
estimate the association between a pair of SNPs and a phenotype.  In the original 
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SNPHarvester as used on case/control data, a chi-square test is the appropriate score 
test to apply as a fast, easily computed hypothesis test for binary data.  For a Cox 
Proportional Hazards model, the appropriate score test is a log-rank test statistic 
(Peto and Peto, 1972).  I therefore decided to implement the log-rank test as a 
function in SNPHarvester to make the best use of the time-to-event data. 
A further limitation to the original SNPHarvester is that it reads in case/control 
phenotype data.  In order to apply a log-rank test I also need SNPHarvester to read in 
and store both the event time and the event type.  This will require an extension of 
the current function to read in the case/control data. 
5.7.1 Log-rank test 
The log-rank test takes time-to-event data for two or more groups and compares their 
survival functions for equivalence. The goal of this test is similar to testing groups 
for equivalence using a t-test, or a non-parametric alternative such as rank-sum test.  
The concept can be visualized by imagining a Kaplan-Meier plot with multiple lines 
representing survivor functions for different groups, and there is separation between 
some or all of the lines.  The statistical question is then identifying whether or not 
these survival functions are truly different - do the subjects in different groups have 
significantly different risks? A standard test for differences between groups would 
not take into account the existence of censored data, and when this is present the log-
rank test or similar tests with different weighting options are an appropriate 
alternative. For the remainder of this explanation of the logrank test, I will use the 
terms 'survive' and 'die' to describe the possible outcomes in a survival analysis, 
rather than the term 'failure' or 'graft failure', which is more appropriate to the renal 
transplant dysfunction study data. 
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For the log-rank test, each observed time point can be considered separately, and we 
can create a contingency table separating individuals by their survival status and 
stratifying them by the grouping variable of interest (see Table 33).  
 
Table 33. Counts of at risk subjects at a single time point t(i) stratified by group and event type 
Event Group 1 Group 2 Group 3 Total 
Died di1 di2 di3 di 
Not Died ni1-di1 ni2-di2 ni3-di3 ni-di 
At risk ni1 ni2 ni3 ni 
 
In this table, the total number of subjects at risk at time ti is denoted by ni, and these 
are divided into K groups (K=3 for this example).  The groups could be different 
treatment groups or, for an example using genetic information, it could be people 
carrying one, two or three risk alleles at a SNP.  The total number who died at this 
time point is denoted by di, divided into di1 (group 1), di2 (group 2) and di2 (group 3).  
The number not dying at a time point is the difference between the total number at 
risk and the number who died, which will include any censored events at this time 
point.  As we consider subsequent time points the number at risk is affected by the 
number of previous deaths, but it is also affected by the number of censored events.  
Subjects who have been censored are no longer at risk, and will not be included in 
the 'at risk' value for subsequent time points.  In this way, subjects who are 
eventually censored still contribute to the calculation of the risk at time points before 
the censoring event, making full use of all the available data.  
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Once the contingency table is created, its contribution to the test statistic is calculated 
in a familiar manner, based on the differences between the observed and expected 
scores and dividing by the variance.  The general form for the test statistic is given in 
matrix notation in Equation 16. 
Equation 16. Test statistic for the logrank test with multiple groups 
𝑄 = 𝑊! 𝑑! − 𝑒!!!!!
!   𝑊!𝑉!𝑊!!!!!
!! 𝑊! 𝑑! − 𝑒!!!!!  
where 𝑑! is a vector containing the number of deaths in each of K-1 groups at time i, 𝑒 is the expected number of deaths in the same groups at the same time point, and 𝑑! − 𝑒!  is the difference between these two vectors.  Any K-1 of the K groups can 
be used, but one must be left out to avoid the centre matrix on the right-hand side of 
Equation 16 being singular.  𝑊! is a vector of length m of weights assigned to the 
each time point.  For a basic log-rank test, this weight is always 1. Tests related to 
the log-rank test such as the modified Peto-Prentice, generalized Wilcoxon and 
Tarone and Ware apply different  weights to the model at different time points. To 
calculate the covariance matrix, we can consider that each time point in the log-rank 
test is a trial with a certain number of successes (deaths) from the available subjects 
(number at risk). Since the number at risk is reduced at each time point, this is a 
series of trials without replacement, and the hypergeometric distribution is 
appropriate.  The covariance matrix for the test statistic for multiple groups is 
therefore derived from the hypergeometric distribution.  𝑉! in Equation 16 is the 
covariance matrix for di, of size K-1 by K, and the formulae for the within-group 
variances in the diagonal elements (Equation 17) and between-group covariances in 
the off-diagonal elements (Equation 18) are given below.   
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Equation 17. Diagonal (variance) elements of the covariance matrix of di 𝑉!!" = 𝑛!"(𝑛! − 𝑛!")𝑑!(𝑛! − 𝑑!)𝑛!!(𝑛! − 1) , 𝑘 = 1,2,… ,𝐾 − 1 
 
Equation 18. Off-diagonal (covariance) elements of the covariance matrix of di 𝑉!"# = 𝑛!"𝑛!"𝑑!(𝑛! − 𝑑!)𝑛!!(𝑛! − 1) , 𝑘, 𝑙 = 1,2,… ,𝐾 − 1, 𝑘 ≠ 𝑙 
In our specific case of two interacting SNPs we have 9 possible groups of people 
with different 2-locus genotypes, so our contingency table will have 9 groups, and 
the covariance matrix will be 8 by 9 elements.   
5.7.2 Implementation 
The implementation of the logrank test extension to SNPHarvester will involve 
changes to the original code in Java, and a call to R from within the Java program to 
carry out the logrank test.  As a reminder, SNPHarvester is a hill-climbing algorithm 
that involves calculating multiple paths through the set of SNPs from random starting 
points (see Chapter 2).  The path through the SNPs is determined by the score of the 
current set of SNPs and the potential replacement SNP, and any increase in score 
will result in a new SNP joining the group and an old SNP being dropped.  The 
algorithm describing a single hill-climbing path through the data is called 
PathSeeker.  Pathseeker is called repeatedly by SNPHarvester to create multiple 
paths through the data from random starting points.  An outline of the PathSeeker 
algorithm taken from the SNPHarvester paper (Sun et al., 2009) is given in Figure 
23.  The changes to be made to this algorithm are: 
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1. The data passed to the PathSeeker algorithm will be a single set of genotypes 
with associated time-to-event phenotype data - an event time and event type 
(censored or failure). 
2. The Score test called by PathSeeker (whenever Score() is seen in the 
algorithm) will be the logrank test instead of the current chi-square test.  
Reading in the time-to-event data will involve creating a new read-data function.  
This function will create arrays to hold the time (in days) and the censoring status 
(0=event, 1=censored) for every response, then read this data in and store it in the 
time and censor arrays. 
The implementation of the log-rank test in SNPHarvester will involve using rJava 
(Urbanek, 2011), an interface between Java and R.  The R package 'Interval' (Fay 
and Shaw, 2010, Schwarz et al., 2010) contains a function called ictest.  This 
function will perform a log-rank test on multiple groups.  An example of the 




Table 34. Time to event data for the log-rank test of two SNPs.   
This table represents the data at a single time point i.  There will be M such tables built and the 
test statistics are summed over all of them.   
  Died Not Died At risk 
AABB di1 ni1-di1 ni1 
AABb di2 ni2-di2 ni2 
AAbb di3 ni3-di3 ni3 
AaBB di4 ni4-di4 ni4 
AaBb di5 ni5-di5 ni5 
Aabb di6 ni6-di6 ni6 
AABB di7 ni7-di7 ni7 
AABb di8 ni8-di8 ni8 
AAbb di9 ni9-di9 ni9 
Total di ni-di ni 
 
The results from SNPHarvester will be the same as when the chi-square score test is 
used.  The program will return a list of SNP pairs whose scores exceed the threshold 
for significance.  The interaction between these SNP pairs is not necessarily 
significant.  As with the original SNPHarvester, the scores represent the combined 
effect of the two SNPs, and these still need to be tested for interactions.  This can 
then be done in a post-processing step by fitting a Cox proportional hazards model 
containing the two SNPs of interest and their interaction. 
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Figure 23. SNPHarvester's PathSeeker algorithm from Yang et al, showing the use of the Score 
function 
5.7.3 Application to Transplant Data 
The ultimate aim of adding a time-to-event option to SNPHarvester is to apply it to 
the renal transplant dysfunction GWAS data.  The current solution of transforming 
 164 
time to event data to a binary variable using a threshold is not optimal, since any data 
that is censored before the threshold time is not used at all.  In application to the 
renal data, SNPHarvester did not find any associations in the 5-year and 10-year 
thresholds, even though there were more failure events.  This is because as time 
passes there are also more censored events, so the number of 'controls' in the binary 
data drops substantially, resulting in a loss of power.  The log rank test, making use 
of the censored data and all of the failure events, may increase power enough to 
detect further interactions. 
5.8 Discussion and conclusions 
The survival analysis of the time to graft failure did not lead to convincing results.  It 
is possible that there are no SNPs that are directly related to post-transplant 
prognosis.  This is an observational study with many unmeasured environmental 
factors that could explain the variability in graft failure times, such as drug 
compliance, drug response, smoking status, diet and exercise.  These may account 
for a great deal of the variability seen in graft survival times, and genetics may play a 
minor role.  It is also possible that we lack power to find associations with the 
number of transplants studied here.  Immunosuppressive drugs are changing and 
possibly improving, and these drugs may be masking genetic effects.  Given that 
there were no strong single-SNP associations it isn't surprising that I have not found 
any significant interactions.  Our initial hypothesis, that there could be interactions 
between genetic variants in donors and recipients, is exactly the problem which 
immunosuppressive drugs are meant to overcome.   
HLA type is known to be an important factor in the success of kidney 
transplantation.  It seems plausible that SNPs in HLA genes may be associated with 
 165 
the survival time of a kidney transplant.  There are several factors which can explain 
why they did not show any association in this study.  First, many transplants are 
matched on HLA type to minimise the risk of rejection.  This will reduce the number 
of mismatches and make any effects more difficult to detect.  Secondly, 
immunosuppressive drugs may mask the effects of mismatches.  Finally, SNPs do 
not uniquely tag the HLA types that have been found to influence prognosis in 
transplantation, so a single-SNP analysis may not pick up on any effect the HLA 
types may have on survival time. 
At the time of writing imputation of SNP data up to 1000 genomes coverage was 
underway.  Analysis of imputed SNPs may lead to stronger single-SNP association 
signals or may confirm that our current top associations are not very strong.  Once 
the imputation analysis is complete, replication of the most likely candidate SNPs 
will be carried out in a European collection of kidney transplant donors and 
recipients (Opelz, 1992).  
The list of interactions suggested by SNPHarvester from the 3-year survival 
phenotype was extensive, but can be reduced drastically by eliminating SNP pairs 
with rare combined genotypes. The results can be reduced further still by eliminating 
SNPs that are known copy-number polymorphisms, as these may lead to poor 
genotype calling.  The remaining pairs represent 15 interaction signals involving 19 
SNPs, which is a sensible set of choices to take forward for replication in another 
cohort of transplant patients.  The extension to SNPHarvester, making full use of the 




6 Discussion and Conclusions 
The overarching theme to this thesis is the search for evidence of interactions 
between genetic variants which are associated with clinical phenotypes.  Each 
chapter presented a piece of work aimed at understanding how, and indeed if, 
statistical analysis can be used to identify these interactions. 
The usual approach in a genome-wide association study is to start with genetic 
variants and apply a statistical method, using associations between SNPs and a 
phenotype to suggest SNPs, genes, pathways or proteins that may be disrupted in 
disease states.  In Chapter 2 I turned this around and started with a real association 
between a pair of SNPs and psoriasis.  I tested methods designed to search for 
interactions in GWAS data to assess their performance on real GWAS data.  Many 
such software packages are tested on simulated data to demonstrate their 
effectiveness.  Simulations are carried out to create samples and genotypes that are 
representative of patterns which are hypothesised to be associated with diseases or 
traits in real samples from populations of interest.  This is a useful technique but can 
be misleading, as the simulated data is often generated using the same assumptions 
that were made in designing the software, and the software is very likely to perform 
well.  These assumptions are a necessary starting point, but they may not reflect 
reality.  It would be far easier to design software if the designer knew what to search 
for, but of course this isn't known until it is found.  For this study, I starting with a 
real sample, with real phenotype information, that had a previously-identified and 
replicated interaction between two SNPs.  My aim was to test software on real data 
with all its complications.  If the software packages had been able to find the real 
interaction, then there would be some evidence that these approaches are sensible.  
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Although applying SNPHarvester followed by the HyperLasso did identify the SNP 
pair in the psoriasis study, it would not have been the most likely candidate for 
follow-up had this truly been a search for novel interactions. With the lack of a good 
replication cohort, it is impossible to say if any of the other more likely candidates 
might be real.  Sparse Partitioning, did not select the previously identified 
interaction.  Asking Sparse Partitioning to search for a large number of predictors 
slows it down considerably.  Given the large number of strong, single-SNP 
associations in this data set it is unlikely that the interaction effect would be strong 
enough to be selected in the model.  However Sparse Partitioning did successfully 
select several independent signals which have since proved to be true associations.   
Finally, Random Jungle was also unsuccessful at selecting the interacting pair.  In 
the analysis for this study I ran the program as recommended by the authors.  It is 
possible that different settings for Random Jungle, such as limiting tree depth, could 
change the results.   
In Chapter 3 I searched for an overall enrichment in low p-values for interactions 
between pairs of SNPs suggested by published protein-protein interactions.  My 
approach of starting from the protein-protein interactions (PPIs) could again be 
considered the reverse of a standard association study.  The PPIs that were my 
starting point have generally been identified in laboratory experiments, and have not 
necessarily been shown to occur in the human body.  The proteins may not be 
expressed in the same tissue, in which case there is no chance for them to interact.  
They may be expressed in the same tissue but be used in other biological processes 
so that they do not come into contact with each other.  However it is reasonable to 
hypothesize that at least some of these PPIs do happen in vivo, and may be disrupted 
in disease states.  Finding an enrichment of statistical interaction signals in these 
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SNPs would have suggested that biological interactions in vivo can be found using 
statistical analysis of SNP data.  However given the rarity of confirmed, convincing 
examples in the literature, and the absence of the enrichment I was hoping to find in 
the PPI study, it is still not clear that this approach is possible or practical.  
Chapter 4 outlined a genome-wide association study in renal transplant dysfunction 
that was a pilot study for the larger project outlined in chapter 5, and eventually these 
two projects were combined.  In both studies the main phenotype was time to graft 
failure, necessitating  the use of survival modelling.  Of particular interest in this 
study was the interaction between donor and recipient genomes, which was assessed 
by including an interaction term between donor and recipient genotypes at the same 
SNP.  Searching between different SNPs, both within and across the two genomes, 
was carried out by the application of SNPHarvester to a binary conversion of the 
survival times.   Although this has produced a list of suggested SNP pairs, these 
require further investigation and replication before there can be confidence in any 
findings. 
Finally, an extension to SNPHarvester to handle time-to-event data was presented.  
The log-rank test, as the score test for the Cox proportional hazards model, provides 
a fast test of association for survival data without fitting the full model.  This is being 
implemented as an alternative function in SNPHarvester.  At the time of writing I 
was still working on this software, with the intention of applying it to the transplant 
study data when it is complete.  This will avoid the necessity of converting the 
survival times to a binary phenotype, which reduces power through the binary 
reclassification and through the loss of information from cases censored before the 
binary decision threshold.   
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Throughout this thesis the hypothesis that SNP-SNP interactions can be found in 
GWAS studies through statistical methods has been tested in several ways, using 
many different methods.  None of these methods has proven successful at finding 
novel interactions or at providing evidence that these interactions exist.  This search 
is certainly not definitive but it does suggest that, as others have found, these 
interactions are not easy to find.  If they do exist in association with human diseases 
and traits they almost certainly have small effect sizes, making them very difficult to 
identify.    
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